News

Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

  • AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer's and Parkison's Disease (AD/PD 2024) taking place in Lisbon, Portugal from March 5-9, 2024.
    03/04/2024

Exit Now! 3 Biotech Stocks to Sell in February 2024

  • The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biotech ETF (XBI), alongside widespread layoffs and fundraising challenges.
    02/21/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Cassava Sciences, Inc. (SAVA) can hold. Click on Rating Page for detail.

The price of Cassava Sciences, Inc. (SAVA) is 20.29 and it was updated on 2024-03-29 01:33:00.

Currently Cassava Sciences, Inc. (SAVA) is in undervalued.

News
    
News

3 small-cap biotechs with potential breakthroughs in 2024

  • There's a reason that many biotech investors prefer to stick with large-cap stocks. Investing in small-cap biotech stocks is not for risk-averse investors.
    Tue, Feb. 06, 2024

Is There Any Hope for Cassava Sciences Stock?

  • Cassava Sciences stock is down due to questions about some of its research. A lot is riding on its late-stage clinical trials to produce favorable data.
    Sat, Feb. 03, 2024

3 Biotech Stocks to Sell in January Before They Crash and Burn

  • The biotech segment is one of the most potent, boasting an impressive Compounding Annual Growth Rate (CAGR) of 13.96% until 2030. However, investing in biotech stocks also bears immense risk, as companies' performance relies heavily on drug approvals.
    Thu, Jan. 25, 2024

Portfolio Protection: 7 Risky Stocks to Drop Right Now

  • With investors moving back towards a “risk-on” stance in recent months, you may think that risky stocks could lead to outsized rewards this year. Yet while more favorable economic and market conditions could extend the current bull market (which started in October) well into 2024, an improving macro picture may not be enough for stocks that have large company-specific risks.
    Fri, Jan. 12, 2024

New SAVAW Warrants Are Trading After Cassava Sciences' Distribution

  • In the biotechnology sector, Cassava Sciences (NADSAQ: SAVA ) remains one of the top clinical-stage companies that investors are watching. Over the past one year, SAVA stock is down by less than 20% but up nearly 9% for the past six months.
    Fri, Jan. 05, 2024
SEC Filings
SEC Filings

Cassava Sciences, Inc. (SAVA) - ARS

  • SEC Filings
  • 03/22/2024

Cassava Sciences, Inc. (SAVA) - CERT

  • SEC Filings
  • 01/03/2024

Cassava Sciences, Inc. (SAVA) - 424B2

  • SEC Filings
  • 01/03/2024

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/08/2023

Cassava Sciences, Inc. (SAVA) - 3

  • SEC Filings
  • 12/08/2023

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/07/2023

Cassava Sciences, Inc. (SAVA) - 3

  • SEC Filings
  • 12/07/2023

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/04/2023

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/24/2023

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/23/2023

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/12/2023

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/25/2023

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/10/2023

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/08/2023

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/02/2023

Cassava Sciences, Inc. (SAVA) - 424B5

  • SEC Filings
  • 05/01/2023

Cassava Sciences, Inc. (SAVA) - ARS

  • SEC Filings
  • 03/16/2023

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/08/2023

Cassava Sciences, Inc. (SAVA) - 5

  • SEC Filings
  • 02/07/2023

Cassava Sciences, Inc. (SAVA) - 424B5

  • SEC Filings
  • 11/21/2022

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/31/2022

Cassava Sciences, Inc. (SAVA) - 3

  • SEC Filings
  • 10/31/2022

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/03/2022

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/12/2022

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/25/2022

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/24/2022

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/16/2022

Cassava Sciences, Inc. (SAVA) - 424B5

  • SEC Filings
  • 07/29/2022

Cassava Sciences, Inc. (SAVA) - S-8

  • SEC Filings
  • 06/10/2022

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/07/2022

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/31/2022

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 04/25/2022

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/29/2022

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/28/2022

Cassava Sciences, Inc. (SAVA) - 5

  • SEC Filings
  • 02/03/2022

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/21/2021

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/20/2021

Cassava Sciences, Inc. (SAVA) - 3

  • SEC Filings
  • 06/14/2021

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/28/2021

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/31/2021

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/18/2021

Cassava Sciences, Inc. (SAVA) - 424B5

  • SEC Filings
  • 02/12/2021

Cassava Sciences, Inc. (SAVA) - 424B5

  • SEC Filings
  • 02/11/2021

Cassava Sciences, Inc. (SAVA) - 3

  • SEC Filings
  • 01/11/2021

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/14/2020

Cassava Sciences, Inc. (SAVA) - 424B5

  • SEC Filings
  • 11/16/2020

Cassava Sciences, Inc. (SAVA) - FWP

  • SEC Filings
  • 11/13/2020

Cassava Sciences, Inc. (SAVA) - 424B5

  • SEC Filings
  • 11/12/2020

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/24/2020

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/21/2020

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/17/2020

Cassava Sciences, Inc. (SAVA) - 424B2

  • SEC Filings
  • 05/05/2020

Cassava Sciences, Inc. (SAVA) - S-3/A

  • SEC Filings
  • 04/09/2020

Cassava Sciences, Inc. (SAVA) - S-3

  • SEC Filings
  • 03/27/2020

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/31/2019

Cassava Sciences, Inc. (SAVA) - 4/A

  • SEC Filings
  • 12/26/2019

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/26/2019

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/20/2019

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/19/2019

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/16/2019

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/15/2019

Cassava Sciences, Inc. (SAVA) - S-1

  • SEC Filings
  • 12/18/2018

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/01/2018

Cassava Sciences, Inc. (SAVA) - 3

  • SEC Filings
  • 10/31/2018

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/09/2018

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/05/2018

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/27/2018

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/26/2018

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/18/2018

Cassava Sciences, Inc. (SAVA) - D

  • SEC Filings
  • 08/30/2018

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/20/2018

Cassava Sciences, Inc. (SAVA) - 3

  • SEC Filings
  • 08/20/2018

Cassava Sciences, Inc. (SAVA) - 424B5

  • SEC Filings
  • 08/17/2018

Cassava Sciences, Inc. (SAVA) - 424B3

  • SEC Filings
  • 08/16/2018

Cassava Sciences, Inc. (SAVA) - S-8

  • SEC Filings
  • 06/19/2018

Cassava Sciences, Inc. (SAVA) - 424B5

  • SEC Filings
  • 02/09/2018

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/08/2017

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/24/2017

Cassava Sciences, Inc. (SAVA) - S-3/A

  • SEC Filings
  • 07/27/2017

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/19/2017

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/05/2017

Cassava Sciences, Inc. (SAVA) - S-3

  • SEC Filings
  • 04/14/2017

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/28/2016

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/18/2016

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 04/15/2016

Cassava Sciences, Inc. (SAVA) - 424B5

  • SEC Filings
  • 12/22/2015

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/15/2015

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/24/2015

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/19/2015

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/18/2015

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/16/2014

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/18/2014

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/15/2014

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/07/2014

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/17/2014

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/10/2014

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/09/2014

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/29/2014

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/19/2014

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 04/14/2014

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 04/04/2014

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/26/2014

Cassava Sciences, Inc. (SAVA) - S-3

  • SEC Filings
  • 02/05/2014

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/16/2013

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/07/2013

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/19/2013

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/10/2013

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/28/2013

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/20/2013

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/13/2013

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/08/2013

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/06/2013

Cassava Sciences, Inc. (SAVA) - 5

  • SEC Filings
  • 02/12/2013

Cassava Sciences, Inc. (SAVA) - 3

  • SEC Filings
  • 02/12/2013

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/10/2012

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/06/2012

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/17/2012

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/17/2012

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/25/2012

Cassava Sciences, Inc. (SAVA) - 4/A

  • SEC Filings
  • 05/30/2012

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/30/2012

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/03/2012

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/29/2011

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/03/2011

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/24/2011

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/05/2011

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/04/2011

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/21/2011

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/10/2011

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/08/2011

Cassava Sciences, Inc. (SAVA) - 3

  • SEC Filings
  • 07/20/2011

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/07/2011

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/22/2011

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/20/2011

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/08/2011

Cassava Sciences, Inc. (SAVA) - 4/A

  • SEC Filings
  • 05/19/2011

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/19/2011

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/04/2011

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 04/04/2011

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/15/2011

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 01/06/2011

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/03/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/04/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/10/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/08/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/02/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/10/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/04/2010

Cassava Sciences, Inc. (SAVA) - S-3/A

  • SEC Filings
  • 08/02/2010

Cassava Sciences, Inc. (SAVA) - S-8

  • SEC Filings
  • 07/29/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/20/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/08/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/02/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/17/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/07/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/03/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/01/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/21/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/19/2010

Cassava Sciences, Inc. (SAVA) - 4/A

  • SEC Filings
  • 05/06/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/06/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/05/2010

Cassava Sciences, Inc. (SAVA) - S-3/A

  • SEC Filings
  • 05/03/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 04/19/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 04/09/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 04/06/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 04/02/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/18/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/12/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/05/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/02/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/26/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/03/2010

Cassava Sciences, Inc. (SAVA) - S-3

  • SEC Filings
  • 02/02/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 01/22/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 01/06/2010

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/08/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/16/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/05/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/19/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/07/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/02/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/29/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/16/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/15/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/11/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/02/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/11/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/04/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/15/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/09/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/15/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/10/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/08/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/26/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/11/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 04/06/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/06/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/04/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/03/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 01/05/2009

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/02/2008

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/04/2008

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/02/2008

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/16/2008

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/03/2008

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/04/2008

Cassava Sciences, Inc. (SAVA) - S-8

  • SEC Filings
  • 07/31/2008

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/02/2008

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/17/2008

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/03/2008

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/27/2008

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/02/2008

Cassava Sciences, Inc. (SAVA) - 4/A

  • SEC Filings
  • 04/02/2008

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 04/02/2008

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/18/2008

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/04/2008

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/03/2008

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/29/2008

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/04/2008

Cassava Sciences, Inc. (SAVA) - 3

  • SEC Filings
  • 01/10/2008

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 01/03/2008

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/11/2007

Cassava Sciences, Inc. (SAVA) - 3

  • SEC Filings
  • 12/11/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/04/2007

Cassava Sciences, Inc. (SAVA) - S-8

  • SEC Filings
  • 11/13/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/02/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/03/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/24/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/05/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/09/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/07/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/02/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/01/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/31/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/30/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/27/2007

Cassava Sciences, Inc. (SAVA) - 4/A

  • SEC Filings
  • 07/24/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/24/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/23/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/03/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/12/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/05/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/04/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/16/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/15/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/11/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/02/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 04/10/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 04/03/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/14/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/12/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/09/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/05/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/02/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/01/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/27/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/26/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/23/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/21/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/20/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/16/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/15/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/14/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/12/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/08/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/06/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/01/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 01/23/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 01/19/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 01/10/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 01/03/2007

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/11/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/04/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/30/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/16/2006

Cassava Sciences, Inc. (SAVA) - 4/A

  • SEC Filings
  • 11/15/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/15/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/13/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/09/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/06/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/02/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/01/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/11/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/29/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/19/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/18/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/11/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/05/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/31/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/10/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/07/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/10/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/03/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/19/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/15/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/13/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/12/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/08/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/06/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/05/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/26/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/24/2006

Cassava Sciences, Inc. (SAVA) - 4/A

  • SEC Filings
  • 05/23/2006

Cassava Sciences, Inc. (SAVA) - S-8

  • SEC Filings
  • 05/22/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/22/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/19/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/17/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/16/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/12/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/11/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/10/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/09/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/03/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 04/10/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 04/04/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/16/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/14/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 03/06/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/23/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/10/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 02/07/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 01/03/2006

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/30/2005

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/20/2005

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 12/16/2005

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/09/2005

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/08/2005

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/04/2005

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/02/2005

Cassava Sciences, Inc. (SAVA) - 3

  • SEC Filings
  • 11/01/2005

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/28/2005

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/12/2005

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 10/06/2005

Cassava Sciences, Inc. (SAVA) - S-3

  • SEC Filings
  • 08/26/2005

Cassava Sciences, Inc. (SAVA) - 4/A

  • SEC Filings
  • 06/14/2005

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/14/2005

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 05/26/2005

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 04/18/2005

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 04/05/2005

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 11/08/2004

Cassava Sciences, Inc. (SAVA) - 424B5

  • SEC Filings
  • 10/08/2004

Cassava Sciences, Inc. (SAVA) - 424B5

  • SEC Filings
  • 09/22/2004

Cassava Sciences, Inc. (SAVA) - 4/A

  • SEC Filings
  • 09/14/2004

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 09/13/2004

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/27/2004

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 06/01/2004

Cassava Sciences, Inc. (SAVA) - S-8

  • SEC Filings
  • 05/11/2004

Cassava Sciences, Inc. (SAVA) - S-3

  • SEC Filings
  • 05/11/2004

Cassava Sciences, Inc. (SAVA) - 3

  • SEC Filings
  • 11/24/2003

Cassava Sciences, Inc. (SAVA) - S-3/A

  • SEC Filings
  • 09/22/2003

Cassava Sciences, Inc. (SAVA) - 424B1

  • SEC Filings
  • 09/22/2003

Cassava Sciences, Inc. (SAVA) - S-3/A

  • SEC Filings
  • 09/04/2003

Cassava Sciences, Inc. (SAVA) - S-3

  • SEC Filings
  • 08/22/2003

Cassava Sciences, Inc. (SAVA) - RW

  • SEC Filings
  • 08/14/2003

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 08/08/2003

Cassava Sciences, Inc. (SAVA) - S-3/A

  • SEC Filings
  • 07/18/2003

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/17/2003

Cassava Sciences, Inc. (SAVA) - 4

  • SEC Filings
  • 07/16/2003

Cassava Sciences, Inc. (SAVA) - S-3

  • SEC Filings
  • 06/23/2003

Cassava Sciences, Inc. (SAVA) - S-8

  • SEC Filings
  • 05/09/2003

Cassava Sciences, Inc. (SAVA) - ARS

  • SEC Filings
  • 04/25/2003

Cassava Sciences, Inc. (SAVA) - ARS

  • SEC Filings
  • 04/24/2002

Cassava Sciences, Inc. (SAVA) - S-8

  • SEC Filings
  • 08/22/2001
Press Releases
StockPrice Release

Cassava update

  • 10/23/2021

Cassava update

  • 10/16/2021
More Headlines
News

Why Cassava Sciences Stock Zoomed 21% Higher This Week

  • The biotech has declared a fresh dividend. The payout is rather atypical -- it's in the form of common stock warrants.
  • 12/15/2023

Why Is Cassava Sciences (SAVA) Stock Up 15% Today?

  • Shares of pharmaceutical specialist Cassava Sciences (NASDAQ: SAVA ) soared earlier Tuesday before giving up most of the gains. Nevertheless, investor enthusiasm spiked over management's decision to issue a warrant distribution to support the ongoing Phase 3 clinical development of oral simulfilam, a promising therapeutic for patients of Alzheimer's disease.
  • 12/12/2023

Why Cassava Sciences Stock Soared Today

  • The biotech significantly modified its board of directors. Two of those incoming directors have extensive experience in the healthcare field; the other comes from the security sphere.
  • 12/08/2023

Alzheimer's Disease Drug Development: Another Lost Year

  • Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anavex's blarcamesine, Cyclo Therapeutics Trappsol Cyclo, Green Valley's GV-971, aromatherapy, and panax ginseng not only inhibit the formation of oxidants but scavenge them and reverse part of their damage.
  • 12/05/2023

Cassava Sciences: Likely Potential Opportunity From Phase 3 Readout Next Year

  • Cassava Sciences is a biotech company focused on developing treatments for Alzheimer's disease with its lead drug candidate, Simufilam. The company has faced allegations of data manipulation and misconduct, but no concrete evidence has been found to support these claims. The Phase 2 data for Simufilam showed potential cognitive benefits in patients with mild AD, but the results were inconsistent and had several limitations.
  • 11/20/2023

7 High-Risk, High-Reward Stocks for the Extreme Contrarian

  • Although the general concept of stock picks for contrarian investors may be universally appealing, when it comes to the most extreme examples, most investors should probably stay away. Basically, while the rewards for when the stars align can be enormously high, they rarely align.
  • 11/14/2023

1 Big Red Flag to Fear When a Stock Is Down

  • Stocks often lose much of their value as a result of controversies. Cassava Sciences is facing a raft of serious allegations from numerous parties.
  • 10/31/2023

Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data

  • Cassava Sciences' stock is highly disputed due to conflicting opinions on the science behind its drug candidate, but outside research supports its apparent drug effect. Biomarkers show strong reductions in patients treated with simufilam, indicating potential efficacy in Alzheimer's disease. The reduction of NfL values over six months is similar to what led to the accelerated approval of Qalsody for ALS.
  • 10/30/2023

7 Stocks That Are Heading for a Train Wreck

  • One of the big slogans favored by CNBC pundit Jim Cramer is, “There's always a bull market somewhere.” I believe that's true.
  • 10/19/2023

SAVA Stock Continues to Plunge on Misconduct Allegations

  • Big problems appear to be getting worse for Cassava Sciences (NASDAQ: SAVA ). The clinical-stage biotech company is a former favorite among retail investors.
  • 10/16/2023

SAVA Stock Alert: Cassava Sciences Addresses Leaked Report

  • Cassava Sciences (NASDAQ: SAVA ) stock was hit hard after the market close yesterday following the publication of a Science article that released the details on a report published by the City University of New York (CUNY). The report accused Cassava collaborator and CUNY faculty member Hoau-Yan Wang of scientific misconduct, including image manipulation.
  • 10/13/2023

Cassava Sciences slumps after leaked report claims 'egregious misconduct' over Alzheimer's drug

  • Cassava Sciences Inc has denied data manipulation after a probe into conduct over its Alzheimer's drug research was leaked yesterday, sending its shares spiralling lower.   Shares of Cassav were down nearly 21% on Friday morning at $13.97.
  • 10/13/2023

Cassava shares plummet after investigation accuses researcher of ‘egregious misconduct'

  • Shares of biotech company Cassava Sciences Inc. were slammed in extended trading Thursday, after the publication Science reported that an investigation accused a neuroscientist who often collaborated with the company of “long-standing and egregious misconduct” in data management and record keeping that raised serious questions about his research.
  • 10/13/2023

Cassava Sciences slumps after leak claims “egregious misconduct”

  • Cassava Sciences Inc has denied data manipulation after a probe into conduct over its Alzheimer's drug research was leaked yesterday, sending its shares into a spiral.   The company's share price on NASDAQ dropped 29.30% on pre-market trades to a nadir of US$8.25 before settling by 20:00 local time, after closing at US$17.56 yesterday.
  • 10/13/2023

Cassava Sciences: Unconvincing Open Label Studies, Upcoming Phase 3, Risky AD Bet

  • The Alzheimer's Disease space is highly volatile, with stock prices reacting to positive or negative data from other companies in the sector. Cassava Sciences, Inc. experienced a correction after initial gains, highlighting the need for caution in the Alzheimer's space. Concerns were raised about the validity of Cassava's phase 2 trial, including participant bias, dropout bias, and the lack of a p-value.
  • 10/11/2023

Why Shares of Cassava Sciences Soared This Week

  • A rash of insider buying helped buoy the clinical-stage biotech's stock. Cassava said it had completed the enrollment of a phase 3 trial for an Alzheimer's disease drug.
  • 10/06/2023

Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY

  • AUSTIN, Texas, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer's disease dementia, today announced that Remi Barbier, President & Chief Executive Officer, is invited to present at the Jefferies Biotech CNS/Neuro Summit in New York on Wednesday, October 11, 2023 at 10:30am ET. A live webcast and archived replay will also be available.
  • 10/05/2023

The 7 Best Meme Stocks to Buy Now: September 2023

  • Given the horrendous performance of meme kings like AMC Entertainment (NYSE: AMC ) and GameStop (NYSE: GME ) lately, searching for the best meme stocks may be the last thing on your mind right now. In fact, considering GME's continued declines, and AMC's capitulation in recent weeks, you may think that the meme stock phenomenon has completely gone the way of the dodo.
  • 09/14/2023

Cassava Sciences Invited to Present in Four Upcoming Investor Conferences

  • AUSTIN, Texas, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer's disease dementia, today announced that it has been invited to present at the following investor conferences.
  • 09/06/2023

Week Of 08/28 Notable Insider Buys

  • Energy Transfer LP, Cassava Sciences, and PENN Entertainment Inc. were discussed in last week's insider trades update. CEO of Sirius XM Holdings Inc., Jennifer Witz, purchased 250,000 shares for over $1 million. Lyft, Inc. shares have risen nearly 20% since the introduction of new CEO David Risher in April, and insiders like the stock also.
  • 09/05/2023

Week Of 08/21 Notable Insider Buys

  • Energy Transfer LP CEO and Executive Vice President make significant insider purchases, with the CEO's YTD purchases totaling around $115 million. Cassava Sciences directors purchase shares amidst discussions of a potential short squeeze, despite the company's net losses and investigations. PENN Entertainment director buys shares following the company's $2 billion agreement with ESPN, despite a slight dip in share prices.
  • 08/29/2023

Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock

  • Cassava Sciences (NASDAQ: SAVA ) stock jumped 5% overnight after director Richard Barry revealed he acquired shares on behalf of his trust. Barry paid $16.80 for each of the 1,905 shares on Aug. 21.
  • 08/24/2023

Why These 3 Stocks Are the Worst Ways to Play Biotech Right Now

  • The tech and growth segments of the market have been having a tremendous 2023 with one glaring exception. Traders have been choosing to avoid biotech stocks amid macroeconomic uncertainty around the sector.
  • 07/13/2023

Cassava Sciences: Positive Data Continues To Derisk Ongoing Phase 3 Trials

  • Cassava Sciences: Positive Data Continues To Derisk Ongoing Phase 3 Trials
  • 07/09/2023

Cassava Sciences (SAVA) Stock Drops Despite Positive Trial Results

  • Cassava Sciences (NASDAQ: SAVA ) stock is well in the red today despite announcing Phase 3 results for its Alzheimer's treatment. Indeed, SAVA stock is down more than 10% at the time of this writing on relatively lukewarm clinical trial news.
  • 07/05/2023

Cassava Sciences: Why Market Skepticism Persists Despite Positive Findings On Simufilam

  • Cassava Sciences' Alzheimer's drug, simufilam, reduced cognitive decline by 38% in a small study, but the results were not statistically significant, raising doubts about its efficacy. Despite a cash reserve of $187.5 million, Cassava's Q1 2023 net loss was $24.3 million, mainly due to increased patient enrollment costs for Phase 3 trials and other simufilam studies. Despite promising results, I maintain my "Strong Sell" recommendation for SAVA stock due to concerns about financial sustainability and the historically high failure rates of Alzheimer's drugs.
  • 07/05/2023

Why Shares of Cassava Sciences Are Dropping Wednesday

  • Simufilam slowed cognitive decline by 38% compared to a placebo after six months for patients with mild to moderate Alzheimer's disease. Cassava Sciences has been the target of shareholder lawsuits, short-seller reports, and government inquiries.
  • 07/05/2023

Cassava Sciences to Present at the Jefferies Global Healthcare Conference

  • AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that its management has been invited to present at the Jefferies Global Healthcare Conference in New York City.
  • 06/01/2023

Cassava (SAVA) Up on Progress With Alzheimers Disease Study

  • Cassava (SAVA) made positive progress with simufilam, an oral drug treatment for Alzheimer's disease dementia. The company's shares gain in the last month.
  • 05/30/2023

Why Shares of Cassava Sciences Jumped This Week

  • The company has a small pipeline. Cassava also released data showing that Simufilam could be useful as an oncology drug.
  • 05/12/2023

Why Is Cassava Sciences (SAVA) Stock Up 15% Today?

  • One of the stocks most in focus today for investors is Cassava Sciences (NASDAQ: SAVA ). Shares of SAVA stock have surged more than 15% as investors digest some promising news about the company's lead drug candidate.
  • 05/09/2023

Buy Cassava Sciences For Imminent Data Readout

  • Buy Cassava Sciences For Imminent Data Readout.
  • 04/26/2023

Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference

  • AUSTIN, Texas, April 26, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that Remi Barbier, President & Chief Executive Officer, has been invited to present at the 2023 H.C. Wainwright BioConnect Investor Conference in New York. In addition, management will be available for one-on-one meetings with institutional investors who are registered to attend this conference.
  • 04/26/2023

Strong Small-Cap Insider Buys: Q1 2023

  • Strong Small-Cap Insider Buys: Q1 2023.
  • 04/26/2023

3 Short-Squeeze Stocks to Keep on Your Radar

  • Short-squeezes have been making headlines in stock trading as an increasingly popular phenomenon. A short squeeze occurs when investors who have bet against a company's stock (by “shorting” it) are forced to buy back their shares to cut their losses.
  • 03/09/2023

Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock

  • Cassava Sciences (NASDAQ: SAVA ) stock rose 11% overnight after director Richard Barry said he bought shares worth $2.3 million. The company is working on an Alzheimer's drug called Simufilam.
  • 03/09/2023

Cassava Sciences stock price outlook is bearish despite insider buy

  • Cassava Sciences (NASDAQ: SAVA) stock price has been in a steep sell-off in the past few months as the enthusiasm of its pipeline wanes. Shares of the biopharmaceutical company were trading at $24.9 on Wednesday, ~51% below the highest level in 2022.
  • 03/09/2023

Cassava Sciences: Open Label Study Data Unconvincing But Indicative Of Good Things

  • Cassava Sciences' phase 2 data was from a nonrandomized trial, therefore unconvincing. However, it indicated drug efficacy quite strongly.
  • 03/05/2023

Cassava Sciences Stock Undervalued with Its $124 Price Target?

  • Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a clinical-stage biotechnology firm that develops drugs for Alzheimer's disease (AD).
  • 01/31/2023

Cassava Sciences' Data Once Again Misunderstood

  • Cassava Sciences' Simufilam staved off cognitive decline in mild Alzheimer's disease. The market reacted negatively anyway.
  • 01/27/2023

Cassava Sciences: Data For Mild Alzheimer's Disease Patients Provides Good Risk/Reward Profile

  • Cassava Sciences released data for over 200 patients in an open-label trial at 12 months. The mild AD subgroup performed unprecedentedly.
  • 01/26/2023

Why Is Cassava Sciences (SAVA) Stock Down 20% Today?

  • One of the biggest decliners in today's market is Cassava Sciences (NASDAQ: SAVA ). Shares of SAVA stock declined more than 20% at today's trough on the company's announced mid-stage results for its Alzheimer's treatment.
  • 01/24/2023

Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors

  • Cassava disappointed Tuesday with midstage results for its oral Alzheimer's treatment and SAVA stock plummeted by a double-digit percentage. The post Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors appeared first on Investor's Business Daily.
  • 01/24/2023

Is a Short Squeeze Coming in Cassava Sciences (SAVA) Stock?

  • Amid surging interest in a wide swath of meme stocks today, retail investors are once again seeing traction in trading unpopular names. That said, other companies many may not necessarily associate with the meme trade are also surging.
  • 01/11/2023

6 Favorite Biotech Bets For 2023

  • Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's a six-pack of favorite biotech ideas for the coming year.
  • 01/09/2023

Why Is Cassava Sciences (SAVA) Stock Up 10% Today?

  • The completion of part of an important study is pushing Cassava Sciences (NASDAQ: SAVA ) stock up today. This clinical-stage biotech company has been volatile this month but has overall performed well.
  • 12/07/2022

Cassava Sciences Stock's Bull Signal Has Never Been Wrong

  • The shares of Cassava Sciences Inc  (NASDAQ:SAVA) are down 3.5% at $32.17 this afternoon, after the company announced a $50 million registered direct stock offering on Friday.
  • 11/21/2022

7 Stocks Rattled by Corporate Scandals and Shenanigans in 2022

  • High inflation and soaring interest rates have been the main factor behind the double-digit stock downturn so far this year, but alongside these macro factors, many stocks have plunged due to more company-specific issues—for example, corporate scandals. These scandals run the gamut, both in the type of scandal and the severity of the scandal.
  • 11/16/2022

Cassava Sciences stock pops after rival experiences setback in Alzheimer's research

  • Yahoo Finance anchors Rachelle Akuffo, Seana Smith and Dave Briggs shares of Cassava moving higher on news that its rival Roche suffered a setback in its Alzheimer's drug research trial.
  • 11/14/2022

Why Is Cassava Sciences (SAVA) Stock Up Today?

  • In today's mixed session, there are plenty of stocks making big moves. Among the biggest movers in this afternoon's session is Cassava Sciences (NASDAQ: SAVA ).
  • 11/14/2022

Cassava Sciences Has a Big Warning for SAVA Stock Short Sellers

  • Shares of Cassava Sciences (NASDAQ: SAVA ) stock are in the spotlight following the company's third-quarter earnings and a stark warning to short sellers. During Q3, the company reported a net loss of $20.3 million, equivalent to an EPS loss of 51 cents per share.
  • 11/07/2022

Trading Ideas On The Upcoming CTAD 2022 Conference

  • The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.
  • 11/02/2022

Why Is Cassava Sciences (SAVA) Stock Down 10% Today?

  • Shares of Cassava Sciences (NASDAQ: SAVA ) declined by as much as 12% today but have since recovered to the $35 range, down about 4%. This was most likely attributed to the release of an article by Probes Reporter.
  • 11/02/2022

Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?

  • Cassava Sciences (SAVA) is expected to provide an update on its pipeline candidates during its third-quarter earnings.
  • 11/01/2022

These Are the Five Best and Worst Performing Small-cap Stocks in September 2022

  • Small-cap stocks are usually young companies that aspire to become large-cap or mega-cap one day.
  • 10/21/2022

SAVA Stock Alert: Cassava Sciences Extends Trial

  • Shares of Cassava Sciences (NASDAQ: SAVA ) stock are in focus after the company announced that it would begin an open-label study on its investigational Alzheimer's disease ( AD ) drug, simufilam. The trial will be eligible for patients who complete either one of its ongoing Phase 3 studies.
  • 10/13/2022

How High Can SAVA Stock Go Once the Controversy Clears?

  • Sometimes, it's hard to know who or what to believe. Such is the case when it comes to the ongoing U.S. Securities and Exchange Commission (SEC) probe into Cassava Sciences (NASDAQ: SAVA ).
  • 09/30/2022

Cassava Sciences Stock: Huge Returns Or Catastrophic Losses

  • This is a highly speculative bet. There has been a constant litany of accusations of wrongdoing on the science.
  • 09/29/2022

Should you buy Cassava Sciences as the stock continue to soar

  • Retail interest in Cassava Sciences (NASDAQ:SAVA) remains far from over. The stock gained more than 6.7% on Wednesday, catapulting it to a 76% increase in value in a month.
  • 09/28/2022

Why Is Cassava Sciences (SAVA) Stock Heating Up Today?

  • Casava Sciences (NASDAQ: SAVA ) stock rose 5% overnight in sympathy with Biogen's (NASDAQ: BIIB ) successful clinical trial of an Alzheimer's drug called lecanemab. Lecanemab, developed with Eisai (OTCMKTS: ESALY ) of Japan, showed a decline in symptoms among 1,795 patients with early Alzheimer's, a brain disease impacting nearly one-third of Americans ages 85 and older.
  • 09/28/2022

5 Investors Betting Big on Cassava (SAVA) Stock

  • Shares of Cassava Sciences (NASDAQ: SAVA ) are down by over 15% following the previous day's gain of 35%. Yesterday, the Securities and Exchange Commission (SEC) announced that it had closed its case on Cassava.
  • 09/23/2022

Cassava: High Risk Speculative Play With Enormous Potential

  • Initiation of a phase 3 program open-label extension study using Simufilam for patients with Alzheimer's Disease is expected in 2nd half of 2022. An ongoing long-term open label study, initiated in March of 2020 is ongoing; Dosing completion is expected Q4 of 2022 and results from it are expected before end of 2022.
  • 09/22/2022

The Huge Reason Cassava Sciences (SAVA) Stock Is Rocketing Higher

  • Deleted: Despite a significant down day for the S&P 500, shares of Cassava Sciences (NASDAQ: SAVA ) closed higher by 35%. That's because the Securities and Exchange Commission (SEC) has closed its case on Cassava following the initiation of an investigation last November.
  • 09/22/2022

Cassava Skyrockets After SEC Clears It Of Tampering With Alzheimer's Data

  • The SEC reportedly cleared an investigation into Cassava Sciences, leading SAVA stock to hit a seven-month high Thursday. The post Cassava Skyrockets After SEC Clears It Of Tampering With Alzheimer's Data appeared first on Investor's Business Daily.
  • 09/22/2022

The SEC Has Officially Cleared Cassava Sciences

  • Cassava Sciences increased by over 10% intraday on positive SEC news. Cassava Sciences is up 26% in the last month while the market is down 7%.
  • 09/22/2022

What Is Going on With Cassava (SAVA) Stock Today?

  • Cassava Sciences (NASDAQ: SAVA ) stock rose nearly 30% on Sept. 20 as speculators bet on the company's efforts against Alzheimer's Disease.
  • 09/21/2022

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

  • AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it has been invited to present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference, being held in New York.
  • 09/08/2022

Cassava Sciences Looks As Good Of A Purchase As Ever

  • Multiple insiders have purchased shares on the open market in the last month. The company has now released positive 100 patient 12-month data.
  • 09/03/2022

Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock

  • Cassava Sciences (NASDAQ: SAVA ) rose 9% overnight on reports director Richard Barry has invested $860,000 in the company's stock. The stock was due to open Aug. 26 at almost $30 per share, a market capitalization of almost $1.2 billion.
  • 08/26/2022

These Are The Ten Best And Worst Performing Small-Cap Stocks In July 2022

  • The small-cap Russell 2000 gained over 10% in July, compared to a jump of 9.1% for the S&P 500.
  • 08/22/2022

Cassava Sciences, Blue Apron, and Revlon Stocks Exploded Out of the Gate Wednesday Morning

  • These vastly different companies have one thing in common.
  • 08/17/2022

Why Is Cassava Sciences (SAVA) Stock Up 20% Today?

  • Cassava Sciences (NASDAQ: SAVA ) rose 20% in overnight trading after board member Sanford Robertson bought 100,000 shares. Chief financial officer Eric Schoen also bought shares.
  • 08/17/2022

Stocks to watch: Apple, Digital World Acquistion Corp, Cassava Science, Canoo

  • Yahoo Finance Live host Seana Smith breaks down the action surrounding trending stocks in after-hours trading, including how the Trump-tied SPAC is filing to delay earnings.
  • 08/16/2022

Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results

  • After at least one year, 50 participants on simufilam experienced a 3.2 point improvement in ADAS-Cog scores whereas another group of 50 participants saw a .2 decline (on average). Acetylcholinesterase inhibitors produce a result between these two points in most individuals after one year.
  • 08/11/2022

10 Stocks to Sell Before They Die

  • This article is excerpted from Tom Yeung's Profit & Protection newsletter dated July 28, 2022. To make sure you don't miss any of Tom's picks, subscribe to his mailing list here.
  • 07/29/2022

Cassava (SAVA) Stock Falls 30% on Report of Criminal Probe

  • Cassava Biosciences (NASDAQ: SAVA ) stock is tumbling 30% in pre-market trading after Reuters reported today that the Justice Department has launched a criminal probe of the company. The news service cited two unnamed individuals as its sources for the article.
  • 07/27/2022

US opens criminal probe into pharma company over potential Alzheimer's drug fraud: report

  • A Texas-based pharmaceutical company is facing a criminal probe into allegations that it manipulated data in its studies on its Alzheimer's drug simuflam on Wednesday.
  • 07/27/2022

Cassava's stock dives 24% after report citing alleged criminal probe of data from Alzheimer's drug trial

  • Shares of Cassava Sciences Inc. SAVA, +0.14% plunged 24.2% in premarket trading on Wednesday after Reuters reported that the Justice Department is investigating whether the company manipulated clinical data for a still-investigational Alzheimer's disease drug, citing people familiar with the matter. Cassava put out a news release in December that said a scientific journal did not find evidence of manipulated data in a 2005 paper authored by the company's scientists after short sellers alleged data manipulation in some previously published research.
  • 07/27/2022

Exclusive-Cassava Sciences faces U.S. criminal probe tied to Alzheimer's drug, sources say

  • The U.S. Justice Department has opened a criminal investigation into Cassava Sciences Inc involving whether the biotech company manipulated research results for its experimental Alzheimer's drug, two people familiar with the inquiry said.
  • 07/27/2022

7 Meme Stocks Trading at a Massive Discount Right Now

  • 'Meme mania' has long since passed, but there may be an opportunity with these seven meme stocks trading at a discount right now. The post 7 Meme Stocks Trading at a Massive Discount Right Now appeared first on InvestorPlace.
  • 07/24/2022

Cassava Sciences And Alzheimer's Disease: A Precipitious Path

  • One probably should not invest in Cassava Sciences until all investigations are completed. Alternative mechanisms of action exist that better explain Cassava Sciences' trial results than the one offered by the company.
  • 06/10/2022

5 Short Squeeze Candidates To Watch This Week: 2 Former SPACs Join Leaderboard With BigBear.AI Topping List

  • Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
  • 05/24/2022

Stay Far Away From Cassava Sciences Amid Data Integrity Criticisms

  • Serious allegations have been made against Cassava by multiple sources, making SAVA stock far too risky for investors at this point. The post Stay Far Away From Cassava Sciences Amid Data Integrity Criticisms appeared first on InvestorPlace.
  • 04/29/2022

Take Full Advantage of Weakness in Cassava Sciences Stock

  • Cassava could run back to $40 again. Should the company get a positive nod for its Alzheimer's treatment, it could see $140 again.
  • 04/26/2022

Cassava Sciences Is a Worthwhile Bet to Consider

  • FDA approval for Simufilam and successful trials of a new blood test to detect Alzheimer's disease could help propel SAVA stock back up. The post Cassava Sciences Is a Worthwhile Bet to Consider appeared first on InvestorPlace.
  • 04/25/2022

The Crowd Has Wisely Soured on Cassava Sciences Stock

  • As perceptions rise that its flagship drug candidate won't make it to market, steer clear of SAVA stock. The post The Crowd Has Wisely Soured on Cassava Sciences Stock appeared first on InvestorPlace.
  • 04/20/2022

Fresh Crop of Concerns Surrounding Alzheimer's Drug Sinks SAVA

  • The shares of Cassava Sciences Inc (NASDAQ:SAVA) are taking a drubbing this morning, last seen down 23.6% at $19.35, and set for their lowest open since January 2021.
  • 04/19/2022

New York Times Report Fresh Allegations On Cassava's Simufilam Alzheimer's Trials, Shares Fall

  • Cassava Sciences Inc (NASDAQ: SAVA) shares are shedding over 20% after The New York Times detailed new allegations related to the studies of the company's experimental Alzheimer's therapy, simufilam. Among the latest concerns highlighted in the NYT article include a report.
  • 04/19/2022

Why Is Cassava Sciences (SAVA) Stock Down Today?

  • SAVA stock is tumbling after The New York Times reported that multiple experts are skeptical about Cassava's data and its main theory. The post Why Is Cassava Sciences (SAVA) Stock Down Today?
  • 04/19/2022

Cassava Sciences Is Worth Considering After Hitting Its Latest Trough

  • The company has no debt and is cash rich. If it receives FDA approval for its Simufilam drug, the SAVA stock price will catapult.
  • 04/11/2022

3 Key Points To Remember About Cassava Sciences

  • Cassava Sciences is trading near its 52 week lows.
  • 04/07/2022

Why Is Cassava Sciences (SAVA) Stock Down Today?

  • Cassava Sciences (SAVA) stock is falling on Tuesday as investors react to a recent fireside chat held by CEO Remi Barbier. The post Why Is Cassava Sciences (SAVA) Stock Down Today?
  • 04/05/2022

Webcast Details for Cassava Sciences' Upcoming Fireside Chat

  • – All Stakeholder Are Welcome to Listen by Webcast –
  • 04/04/2022

Here's Why Cassava Sciences Stock Could Make a Comeback

  • It helps to have plenty of cold, hard cash.
  • 04/01/2022

Risk-on Biotech Investors Should Buy Cassava Sciences

  • SAVA stock is volatile but worthwhile after opinion shifts in its favor. Remember, it has a blockbuster Alzheimer's drug nearing launch.
  • 03/30/2022

Keep Risk in Mind With Cassava Sciences Stock, but Don't Dismiss Upside Potential

  • If you can stomach the risk and have experience investing in clinical stage biotech plays, SAVA stock remains an interesting situation. After its recent weakness, you may find now to be the right time to initiate a position.
  • 03/15/2022

Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know

  • In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $37.31, marking a +0.54% move from the previous day.
  • 03/04/2022

Cassava Sciences Is in a Bleak Midwinter Waiting for Spring and Better Days

  • SAVA stock is driven by updates on clinical Phase 3 trials and lots of irrationality. Meanwhile, an FDA approval may take quite some time.
  • 03/03/2022

Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know

  • Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $42.51, moving +1.19% from the previous trading session.
  • 02/25/2022

Why Cassava Sciences Is Still a High-Risk Play

  • As it's not set in stone that Cassava Sciences will be able to bring simulfilam to market, you should approach SAVA stock cautiously. The post Why Cassava Sciences Is Still a High-Risk Play appeared first on InvestorPlace.
  • 02/25/2022

Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know

  • Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $49.22, moving +1.07% from the previous trading session.
  • 02/15/2022

The FDA Deals Another Blow To Cassava Sciences' Bears

  • The FDA Deals Another Blow To Cassava Sciences' Bears
  • 02/11/2022

Benzinga's Daily Brief On Trending Tickers For Feb. 11, 2022: Cassava Sciences, Cleveland Cliffs, GameStop, and More

  • Benzinga's “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks. The data on the trending tickers is compiled from a list of most-discussed tickers on the popular Reddit forum WallStreetBets.
  • 02/11/2022

Here is where you can Cassava Sciences stock (SAVA): it is up 7% today

  • After dropping since mid-November, the price of Cassava Sciences stock (SAVA) has bounced back and today it is up 7.78%. The current bullish outlook is a result of a denial by the FDA against Citizen Petitions Filed on Behalf of Short Selling Clients.
  • 02/11/2022

Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know

  • Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $47.12, moving +0.17% from the previous trading session.
  • 02/08/2022

Does Cassava Sciences and Its Alzheimer's Drug Really Have What It Takes?

  • Can Cassava Sciences' Simufilam drug really treat Alzheimer's? Who really knows.
  • 02/08/2022

Keep an Eye on $60 as a Target Price for Cassava Sciences

  • As long as you're using a moderate position size, it's fine to hold SAVA stock as it has a tendency to move fast and far from time to time. The post Keep an Eye on $60 as a Target Price for Cassava Sciences appeared first on InvestorPlace.
  • 02/07/2022

Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity

  • Seeking Alpha longs have warned that increasing short positions in Cassava Sciences stock could result in a “short squeeze.”. For at least several days, comments on Seeking Alpha have disclosed that retail longs are receiving telephone calls from their brokers, asking if they are willing to loan their shares.
  • 02/02/2022

Are Herron Therapeutics, Cassava Sciences Ripe for a Short Squeeze?

  • As I pointed out in a previous discussion, short selling is not for the faint of heart and is probably best left to experienced traders. But there is an opportunity for investors to make money by keeping an eye on companies that could be subject to a short squeeze.
  • 01/25/2022

Cassava Sciences Is an Exciting Roll-the-Dice Biotech Trade

  • Take a wild ride -- but keep your position size small, please -- as SAVA stock could return to all-time highs or plummet to new depths soon. The post Cassava Sciences Is an Exciting Roll-the-Dice Biotech Trade appeared first on InvestorPlace.
  • 01/24/2022

6 Top Biotech Ideas For 2022

  • 6 Top Biotech Ideas For 2022
  • 01/20/2022

Cassava Sciences Stock Is Still Risky but Has Plenty of Upside Potential

  • Still, weighing risk against potential gains, the odds with SAVA stock may be on your side. If you are active in similar types of plays, consider it one to put on your watchlist.
  • 01/18/2022

INmune Bio, The Biotech In My Stable For After Cassava Sciences

  • Both Cassava Sciences and INmune Bio have brought impressive results on neuroinflammation and neurodegeneration. I expect INmune Bio's XPro to yield impressive results in its phase 2 trials like Cassava Sciences' simufilam did.
  • 01/17/2022

7 High Risk Stocks That Are Worth The Volatile Vibes

  • These seven high risk stocks made wild moves in 2021, but still have the potential to rocket higher. All are full of both risk and reward.
  • 01/10/2022

Where Will Cassava Sciences Be in 1 Year?

  • It could be a make-or-break year for the clinical-stage biotech.
  • 01/07/2022

Cassava Sciences, Inc. - The Short Squeeze Has Started

  • I provide and compare historical data from the GameStop and AMC short squeezes that occurred last year to Cassava Sciences. The short squeeze for Cassava Sciences has already started – as was the case for GameStop, recall that the increase in price-per-share for GameStop occurred over 12 trading days.
  • 01/06/2022

Cassava Sciences: Likelihood Of FDA Success Implies 11x Upside

  • The market is pricing in an approximately 6% chance of FDA approval for Cassava Sciences' Alzheimer's small molecule pill, Simufilam. The distribution of 147,000 Simufilam to more than 250 Alzheimer's patients in at least 16 investigator sites shows zero drug-related serious adverse events vs. 69% occurrence of ARIA with Biogen.
  • 01/03/2022

Is the Options Market Predicting a Spike in Cassava Sciences (SAVA) Stock?

  • Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
  • 12/31/2021

Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam

  • I do not believe that a short position in Cassava Sciences stock is rational.
  • 12/30/2021

7 of the Best Meme Stocks for 2022 to Buy Now

  • Although the meme stocks phenomenon is sagging in popularity, these seven current and/or former Reddit favorites could make another "to the moon" move or two in 2022. The post 7 of the Best Meme Stocks for 2022 to Buy Now appeared first on InvestorPlace.
  • 12/30/2021

5 Stocks I'd Sell Right Now

  • These could be some of the worst-performing and riskiest investments in 2022.
  • 12/29/2021

Best Health Care Stocks To Buy Now? 3 For Your 2022 Watchlist

  • Health care stocks worth knowing as the Omicron Covid-19 variant sweeps the globe.
  • 12/28/2021

SAVA Stock Alert: What Is Going on With Red-Hot Cassava Sciences Today?

  • Biotech company Cassava saw a big jump today on positive news related to its Alzheimer's disease treatment. Keep an eye on SAVA stock.
  • 12/21/2021

Cassava Sciences Stock: Here We Go Again

  • While the interim data looks fantastic, and some are pushing for early approval of the drug by the FDA, some questions remain surrounding the academic integrity of the work.
  • 12/21/2021

Science Journal Finds No Evidence To Data Manipulation By Cassava Sciences' In 2005 Publication

  • Cassava Sciences Inc (NASDAQ: SAVA) has been informed by the Neuroscience journal that there is no evidence to support claims of data manipulation in a 2005 paper authored by the Company and its scientific collaborators.  "Another science journal has cleared us of allegations," said Remi Barbier, President & CEO.
  • 12/21/2021

Top Penny Stocks To Buy? 3 Former Stocks Under $5 To Watch Now

  • Are these former penny stocks on your list to buy right now or is the rally over? The post Top Penny Stocks To Buy?
  • 12/21/2021

SAVA Stock: The Social Media Chatter That Has Cassava Sciences Trending Today

  • Cassava Sciences (SAVA) stock is getting some extra attention today from traders on social media and we've got all the details. The post SAVA Stock: The Social Media Chatter That Has Cassava Sciences Trending Today appeared first on InvestorPlace.
  • 12/21/2021

Cassava Stock Surges as Social Media Buzz Intensifies

  • The shares of Cassava Sciences Inc (NASDAQ:SAVA) are surging before the bell, last seen up 33.6% at $49.13, as the heavily shorted stock gains popularity on social media this morning.
  • 12/21/2021

Cassava Sciences Stock (SAVA): Why The Price Surged

  • The shares of Cassava Sciences, Inc. (NASDAQ: SAVA) were halted this morning. This is why it happened.
  • 12/21/2021

7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts

  • These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. The post 7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts appeared first on InvestorPlace.
  • 12/07/2021

Interview With Cassava Sciences' CEO Remi Barbier - Data Integrity, Elon Musk, And The Haters

  • We have a wide-ranging phone interview with Cassava Sciences' CEO Remi Barbier. He addresses crazy accusations and data safeguards.
  • 12/06/2021

Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing

  • Cassava Sciences has been one of 2021's best stocks. We can learn some things from Cassava to help us find the next great biotech or growth & innovation stock.
  • 12/01/2021

Is the Options Market Predicting a Spike in Cassava Sciences (SAVA) Stock?

  • Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
  • 11/26/2021

Cassava Sciences Just Returned to the Buy Zone

  • There's no need to panic about SAVA stock, as Cassava Sciences just launched an important study focused on treating Alzheimer's disease. The post Cassava Sciences Just Returned to the Buy Zone appeared first on InvestorPlace.
  • 11/22/2021

Will Cassava Sciences Stock Continue To See Lower Levels?

  • The stock price of Cassava Sciences plunged 23% yesterday after a report that the U.S. SEC is investigating the company over allegations of data manipulation for its experimental Alzheimer's treatment - Simufilam. [1] SAVA stock saw a large fall in September following a citizen petition filed to.
  • 11/19/2021

Cassava Sciences Kickstarts Second Late-Stage Alzheimer's Trial With Simufilam

  • Cassava Sciences Inc (NASDAQ: SAVA) has initiated a second Phase 3 study of simufilam in patients with Alzheimer's disease.  The second Phase 3 study is designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg over 78 weeks over 78 weeks in approximately 1,000 patients.
  • 11/18/2021

Is An Accelerated Approval Likely For Cassava Sciences?

  • Cassava Sciences is a company with a promising Alzheimer's Drug candidate. The FDA has a process called accelerated approval that allows for drugs to be approved for use before the finishing of drug trials.
  • 11/18/2021

Cassava (SAVA) Down on Report of SEC Investigation Into AD Program

  • Cassava (SAVA) tanks on reports of an investigation by the SEC related to data reports on its AD candidate.
  • 11/18/2021

3 Biotech Stocks That Have More Than Tripled so far This Year

  • But can they keep up the momentum?
  • 11/18/2021

See Why Cassava Sciences Shares Are Falling On Wednesday?

  • The Wall Street Journal reported that the SEC had launched a probe into claims that Cassava Sciences Inc (NASDAQ: SAVA) manipulated data key to its case for its experimental Alzheimer's drug simufilam. The report comes just two days after Cassava, in an SEC filing, revealed that “certain government agencies” had asked the Company for documentation.
  • 11/17/2021

Why Cassava Sciences Is Sliding Lower Today

  • Allegations of data manipulation that hammered the company -- and its stock price -- this summer won't be easily forgotten.
  • 11/17/2021

Today's Hot Penny Stocks: What's Moving ZSAN, AVGR and CEI Higher Wednesday?

  • Today's hot penny stocks are catching the eyes of investors and we're diving into everything investors need to know about them on Wednesday! The post Today's Hot Penny Stocks: What's Moving ZSAN, AVGR and CEI Higher Wednesday?
  • 11/17/2021

7 Short-Squeeze Stocks Loaded With High-Risk, High-Reward Upside

  • Here are seven of the top short-squeeze stocks investors may want to keep their eye on, as retail investors lay and wait for the next squeeze. The post 7 Short-Squeeze Stocks Loaded With High-Risk, High-Reward Upside appeared first on InvestorPlace.
  • 11/11/2021

Biogen Vs. Cassava Sciences Stock: Which Is The Better Buy?

  • Neurological diseases including Alzheimer's are a huge unmet need that BIIB and SAVA are working on solutions for. BIIB's diversification, low sentiment, and profitability make it more suitable to a wider audience of investors.
  • 11/11/2021

Cassava Sciences: Cash Is King

  • The company's Q3 earnings "missed" expectations which is laughable. Cassava is increasing spending to get its phase 3 trials off the ground.
  • 11/10/2021

An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why

  • An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why
  • 11/10/2021

Cassava Sciences Stock: Top Contender For A Continued Short Squeeze

  • Cassava Sciences Stock: Top Contender For A Continued Short Squeeze
  • 11/10/2021

Cassava Sciences Needs Time and Data to Prove Itself Before You Buy

  • Even as SAVA stock whipsaws in both directions, Cassava's commitment to treating Alzheimer's disease remains as firm and steady as ever. The post Cassava Sciences Needs Time and Data to Prove Itself Before You Buy appeared first on InvestorPlace.
  • 11/09/2021

Cassava Is a Sell After Accusations of Data Manipulation

  • After Cassava was accused of multiple improprieties for its star Simufilam drug, investors should sell the vast majority of their SAVA stock. The post Cassava Is a Sell After Accusations of Data Manipulation appeared first on InvestorPlace.
  • 11/09/2021

Cassava Sciences' Hypothesis Raises Doubts

  • Central to Cassava's hypothesis requires amyloid beta-42 to induce an altered conformation of structural protein filamin A and that sumifilam restores altered filmin A back to its native state. Researchers have demonstrated that mutations that cause familial AD, amyloid beta-40, and -42 production is more likely to be reduced or abolished due to decreased enzymatic activity of gamma-secretase.
  • 11/08/2021

4 Top Biotech Stocks To Watch This Week

  • Check out these biotech stocks that could prove to be valuable additions to your portfolio.
  • 11/08/2021

Short Squeeze Stocks: PROG, SAVA and 3 Others Experts Think Are Ready to Pop

  • Fintel's list of short squeeze stocks to watch for this week is in. Here are the names that investors should be watching.
  • 11/08/2021

Cassava Sciences: A Close Look

  • On Nov 4, Cassava Sciences issued a PR which headline reads, 'Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences' And the sub-heading: It states, "No evidence of data manipulation was found for Western blot data."
  • 11/06/2021

Stocks Heading Into Holiday Season With Record Highs

  • Stocks continued their run of near daily record highs heading into November, as investors digested a slew of economic updates and earnings reports.
  • 11/05/2021

Alzheimer's - Cassava Sciences, Cortexyme Or Anavex: Who Will Come On Top?

  • Cassava Sciences' Simufilam is now seen as the best hope to treat all patients in Alzheimer's disease after disappointment in Cortexyme's data.
  • 11/05/2021

Cassava Sciences (SAVA) Stock: Why The Price Surged Today

  • The stock price of Cassava Sciences Inc (NASDAQ: SAVA) surged 48.96% today. This is why it happened.
  • 11/04/2021

Why Did Cassava Sciences Stock Jump 49% Today?

  • Journal of Neuroscience has informed Cassava Sciences Inc (NASDAQ: SAVA) that there is no evidence of data manipulation in an article published in July 2012 describing a new approach to treating Alzheimer's disease.  The peer-reviewed article was co-authored by scientists and academic collaborators for Cassava Sciences and is foundational to simufilam, the Company's lead Alzheimer's candidate.
  • 11/04/2021

Cassava Sciences Stock Surges on Alzheimer's Article Update

  • Cassava Sciences Inc (NASDAQ:SAVA) is soaring today, up 46.1% to trade at $82.80 at last glance, after the company said the Journal of Neuroscience found no evidence of data manipulation in its 2012 article describing a new approach to treating Alzheimer's.
  • 11/04/2021

Cassava Sciences: Major Hit To The Bears

  • No evidence of data manipulation.
  • 11/04/2021

Why Cassava Sciences Shares Are Rising

  • Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher after a review by the Journal of Neuroscience showed there is no evidence of data manipulation in a 2012 company technical paper. "I've never doubted the integrity of our people or science," said Remi Barbier, President & CEO.
  • 11/04/2021

SAVA Stock Alert: Why Cassava Sciences Is Rocketing 50% Higher Today

  • Cassava Sciences just got good news. SAVA stock is soaring as the company celebrates the end of its manipulated data accusations.
  • 11/04/2021

Is it too risky to buy Cassava Sciences as Quintessential says the stock is worthless?

  • On Wednesday, Cassava Sciences Inc. (NASDAQ:SAVA) shares plunged more than 7% after Quintessential Capital management released a report saying the stock is worthless. The firm called for shorts to swoop in claiming its Alzheimer's drug Simufilam seems to be based on forged research.
  • 11/03/2021

Cassava Sciences Is on a Bumpy Road to Multibagger Status

  • Based on analyst estimates for the next ten years, SAVA stock could be worth three times more if its Alzheimer's drug succeeds. The post Cassava Sciences Is on a Bumpy Road to Multibagger Status appeared first on InvestorPlace.
  • 11/03/2021

Cassava Sciences (SAVA) to Post Q3 Earnings: What's in Store?

  • Investors will watch for updates on its lead candidate, sumifilam, for Alzheimer's disease in Cassava's (SAVA) Q3 earnings call.
  • 11/01/2021

Cassava Sciences Stock: Massive Potential Marred By Controversy

  • Cassava Sciences, Inc. is a pre-revenue biotechnology company. The company specializes in neurodegenerative diseases, such as Alzheimer's disease.
  • 11/01/2021

Cassava Sciences' Stock Remains an Enigma

  • Cassava Sciences has lost 26% for the month through Oct. 27. Entering October, SAVA stock looked to go on a big run.
  • 11/01/2021

Buy SAVA Stock on Dips as its Phase 3 Trial Moves Along

  • There's no way to mitigate its high risk nature completely. But if you're bullish on Simulfilam?
  • 10/29/2021

Cassava Sciences: Welcome To The Casino

  • There is a lot of hope with this one for those suffering from Alzheimer's.
  • 10/25/2021

3 Biotech Stocks That Are Ridiculously Overpriced

  • They've risen too far, too quickly.
  • 10/20/2021

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)

  • New York, New York--(Newsfile Corp. - October 19, 2021) -  The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=20539&from=5
  • 10/19/2021

SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - October 19, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20530&wire=5
  • 10/19/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - October 19, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=20524&from=5
  • 10/19/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadline - SAVA

  • New York, New York--(Newsfile Corp. - October 18, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and certain of its officers. The class action, filed in the United States District Court for the Western District of Texas, and docketed under 21-cv-00856, is on behalf of a class consisting of all persons and entities other than Defendants that...
  • 10/18/2021

SHAREHOLDER ALERT: SAVA WDH HNST: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

  • NEW YORK, NY / ACCESSWIRE / October 18, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
  • 10/18/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - October 18, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
  • 10/18/2021

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of KPLT, SAVA and SPPI

  • NEW YORK, NY / ACCESSWIRE / October 17, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
  • 10/17/2021

Rosen, Top Ranked Investor Counsel, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important October 26 Deadline in Securities Class Action - SAVA

  • New York, New York--(Newsfile Corp. - October 16, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline.SO WHAT: If you purchased Cassava Sciences securities during the Class Period you may be entitled to compensation without payment of any out of...
  • 10/16/2021

Cassava Update

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 16, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal...
  • 10/16/2021

(SAVA) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading Cassava Class Action Lawsuit

  • SAN DIEGO, Oct. 16, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). The class action is on behalf of shareholders who purchased Generac common stock between September 14, 2020 and August 27, 2021.
  • 10/16/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadline - SAVA

  • NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and certain of its officers.  The class action, filed in the United States District Court for the Western District of Texas, and docketed under 21-cv-00856, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Cassava securities between September 14, 2020 and August 27, 2021, inclusive (the "Class Period").
  • 10/15/2021

INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

  • Los Angeles, California--(Newsfile Corp. - October 15, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
  • 10/15/2021

LAWSUIT FILED - CASSAVA SCIENCES Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

  • Boston, Massachusetts--(Newsfile Corp. - October 15, 2021) -  Block & Leviton announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) for potential securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/sava.What is this all about?Earlier today the National Institute of Health "NIH" indicated it is aware...
  • 10/15/2021

Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021

  • Philadelphia, Pennsylvania--(Newsfile Corp. - October 15, 2021) - Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period"). If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please...
  • 10/15/2021

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SAVA, SAM and APPH

  • NEW YORK, NY / ACCESSWIRE / October 15, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
  • 10/15/2021

Cassava Class Action Reminder

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 14, 2021) -  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in Cassava stock or options...
  • 10/14/2021

CLASS ACTION UPDATE for KPLT, SAVA and HYZN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

  • NEW YORK, NY / ACCESSWIRE / October 14, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.
  • 10/14/2021

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

  • Los Angeles, California--(Newsfile Corp. - October 14, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
  • 10/14/2021

SAVA LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Cassava Sciences, Inc. Shareholders

  • New York, New York--(Newsfile Corp. - October 14, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/cassava-sciences-inc-loss-submission-form/?id=20435&from=5
  • 10/14/2021

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)

  • New York, New York--(Newsfile Corp. - October 13, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=20420&from=5
  • 10/13/2021

Lawsuits Filed Against SAVA, SPPI and APPH - Jakubowitz Law Pursues Shareholders Claims

  • NEW YORK, NY / ACCESSWIRE / October 13, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.
  • 10/13/2021

CASSAVA SCIENCES, INC. (SAVA) SHAREHOLDER LAWSUIT DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - October 13, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period"). The lawsuit filed in the...
  • 10/13/2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences (SAVA) Investors with $250K+ Losses to Contact Firm's Attorneys Now, Deadline Approaching in Securities Fraud Lawsuit

  • San Francisco, California--(Newsfile Corp. - October 13, 2021) -  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and omissions concer
  • 10/13/2021

SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit

  • LOS ANGELES, Oct. 13, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Class Period: September 14, 2020 and August 27, 2021 Lead Plaintiff Deadline: October 26, 2021  If you wish to serve as lead plaintiff of the Cassava lawsuit, you can submit your contact information at https://www.glancylaw.com/cases/cassava-sciences-inc/.
  • 10/13/2021

SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - October 13, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20389&wire=5
  • 10/13/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - October 13, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=20378&from=5
  • 10/13/2021

Investor Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc. (SAVA)

  • Radnor, Pennsylvania--(Newsfile Corp. - October 12, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021, inclusive (the "Class Period").CLICK HERE TO SUBMIT YOUR CASSAVA LOSSESLEAD PLAINTIFF DEADLINE: October 26, 2021CLASS PERIOD: ...
  • 10/12/2021

Cassava Shareholder Alert

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 12, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in Cassava stock or...
  • 10/12/2021

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SAVA, HYRE and APPH

  • NEW YORK, NY / ACCESSWIRE / October 12, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.
  • 10/12/2021

INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

  • Los Angeles, California--(Newsfile Corp. - October 12, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
  • 10/12/2021

CASSAVA SCIENCES, INC. (SAVA) SHAREHOLDER LAWSUIT DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - October 12, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period"). The lawsuit filed in the United...
  • 10/12/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - October 12, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
  • 10/12/2021

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)

  • New York, New York--(Newsfile Corp. - October 12, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=20329&from=5
  • 10/12/2021

SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - October 11, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20315&wire=5
  • 10/11/2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Cassava Sciences (SAVA) Investors of Pending Securities Fraud Lawsuit, Encourages Investors with $250K+ Losses to Contact Firm's Attorneys Now

  • San Francisco, California--(Newsfile Corp. - October 11, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now. Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements...
  • 10/11/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - October 11, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=20299&from=5.
  • 10/11/2021

Cassava Sciences: Fine Trading Stock, Terrible Investment

  • SAVA stock has fallen sharply in recent weeks. However, it's still a rather expensive bet on a controversial drug heading into Phase 3 trials.
  • 10/11/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - October 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
  • 10/11/2021

Important Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. Investors of Securities Fraud Class Action Lawsuit

  • RADNOR, Pa., Oct. 10, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors of Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Cassava securities between September 14, 2020 and August 27, 2021 , inclusive (the "Class Period").
  • 10/10/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadline - SAVA

  • New York, New York--(Newsfile Corp. - October 9, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and certain of its officers. The class action, filed in the United States District Court for the Western District of Texas, and docketed under 21-cv-00856, is on behalf of a class consisting of all persons and entities other than Defendants that purchased...
  • 10/09/2021

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important October 26 Deadline in Securities Class Action – SAVA

  • NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the “Class Period”), of the important October 26, 2021 lead plaintiff deadline. SO WHAT: If you purchased Cassava Sciences securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem
  • 10/09/2021

Cassava Update

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 9, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.If you suffered losses exceeding $50,000 investing in Cassava stock or options between...
  • 10/09/2021

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

  • Los Angeles, California--(Newsfile Corp. - October 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
  • 10/08/2021

CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. Shareholders of Securities Fraud Class Action Lawsuit

  • Radnor, Pennsylvania--(Newsfile Corp. - October 8, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Cassava securities between September 14, 2020 and August 27, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who purchased or acquired Cassava securities during the Class Period may, no later...
  • 10/08/2021

INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

  • Los Angeles, California--(Newsfile Corp. - October 7, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
  • 10/07/2021

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PHG, SESN and SAVA

  • NEW YORK, NY / ACCESSWIRE / October 7, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
  • 10/07/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadline - SAVA

  • NEW YORK, Oct. 7, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and certain of its officers.  The class action, filed in the United States District Court for the Western District of Texas, and docketed under 21-cv-00856, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Cassava securities between September 14, 2020 and August 27, 2021, inclusive (the "Class Period").
  • 10/07/2021

Cassava Class Action Reminder

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 7, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or...
  • 10/07/2021

HAGENS BERMAN Encourages Cassava Sciences (SAVA) Investors with $250K+ Losses to Contact Firm's Attorneys Now, Securities Fraud Class Action Pending

  • San Francisco, California--(Newsfile Corp. - October 7, 2021) -  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and omissions concern
  • 10/07/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - October 7, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=20216&from=5
  • 10/07/2021

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)

  • New York, New York--(Newsfile Corp. - October 7, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=20199&from=5
  • 10/07/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - October 6, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
  • 10/06/2021

INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

  • Los Angeles, California--(Newsfile Corp. - October 6, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
  • 10/06/2021

SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - October 6, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20179&wire=5
  • 10/06/2021

Cassava Sciences Starts Late-Stage Simufilam Study In Alzheimer's Patients

  • Cassava Sciences Inc (NASDAQ: SAVA) initiated an initial Phase 3 efficacy study of simufilam, an investigational drug for patients with Alzheimer's disease.  A second Phase 3 efficacy study of simufilam in Alzheimer's disease is expected to begin by year-end.
  • 10/06/2021

CASSAVA SCIENCES, INC. (SAVA) SHAREHOLDER LAWSUIT DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - October 6, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period"). The lawsuit filed in the United...
  • 10/06/2021

Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer's Disease

  • AUSTIN, Texas, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, announced today it has initiated an initial Phase 3 efficacy study of simufilam, the Company's investigational drug for patients with Alzheimer's disease. A second Phase 3 efficacy study of simufilam in Alzheimer's disease is expected to begin by year end.
  • 10/06/2021

Cassava Sciences Stock Could Explode as FDA Approval Is a Real Possibility

  • SAVA stock is volatile but worthwhile as its Alzheimer's drug inches closer to commercialization. Risk tolerance is needed, but likely smart The post Cassava Sciences Stock Could Explode as FDA Approval Is a Real Possibility appeared first on InvestorPlace.
  • 10/06/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - October 6, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=20159&from=5
  • 10/06/2021

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important October 26 Deadline in Securities Class Action - SAVA

  • NEW YORK, Oct. 5, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline. SO WHAT: If you purchased Cassava Sciences securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
  • 10/05/2021

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PHG, LIVE and SAVA

  • NEW YORK, NY / ACCESSWIRE / October 5, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
  • 10/05/2021

Cassava Shareholder Alert

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 5, 2021) -  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or options...
  • 10/05/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - October 5, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
  • 10/05/2021

HAGENS BERMAN Notifies Cassava Sciences (SAVA) Investors of October Deadline in Securities Class Action, Encourages Investors with $250K+ Losses to Contact Firm's Attorneys Now

  • San Francisco, California--(Newsfile Corp. - October 5, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and omissions concerning...
  • 10/05/2021

Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021

  • Philadelphia, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period"). If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please...
  • 10/05/2021

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)

  • New York, New York--(Newsfile Corp. - October 5, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=20126&from=5
  • 10/05/2021

SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - October 4, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20114&wire=5
  • 10/04/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - October 4, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=20110&from=5
  • 10/04/2021

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

  • Los Angeles, California--(Newsfile Corp. - October 4, 2021) -   The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
  • 10/04/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - October 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
  • 10/04/2021

Use Cassava Sciences Stock Weakness as Buy Opportunity Ahead of Phase 3

  • If Cassava Sciences' Alzheimer drug can continue to produce solid results, it could see FDA approval before the end of 2022. SAVA stock may not be oversold for long.
  • 10/04/2021

What to Make of Cassava Sciences' Late September Rally

  • Cassava Sciences gained 50% in the second half of September. Now the question is, can SAVA stock keep up momentum in October?
  • 10/04/2021

Cassava Class Action Reminder

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 3, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or options...
  • 10/03/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadline - SAVA

  • New York, New York--(Newsfile Corp. - October 2, 2021) -  Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and certain of its officers. The class action, filed in the United States District Court for the Western District of Texas, and docketed under 21-cv-00856, is on behalf of a class consisting of all persons and entities other than Defendants that purchased...
  • 10/02/2021

Investor Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc. - SAVA

  • Radnor, Pennsylvania--(Newsfile Corp. - October 2, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors of Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who purchased or acquired Cassava securities during the Class Period may, no...
  • 10/02/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadline - SAVA

  • New York, New York--(Newsfile Corp. - October 1, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and certain of its officers. The class action, filed in the United States District Court for the Western District of Texas, and docketed under 21-cv-00856, is on behalf of a class consisting of all persons and entities other than Defendants that...
  • 10/01/2021

HAGENS BERMAN Alerts Cassava Sciences (SAVA) Investors to Approaching Deadline in Securities Class Action, Encourages Investors with $250K+ Losses to Contact Firm's Attorneys Now

  • San Francisco, California--(Newsfile Corp. - October 1, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now. Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVAContact An Attorney Now: SAVA@hbsslaw.com844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and omissions concerning Casava's Alzh
  • 10/01/2021

Cassava Stock Has Reached a Positive Turning Point

  • Cassava is rebounding and SAVA stock may rally back to its old highs as it fends off a short-selling attack. The post Cassava Stock Has Reached a Positive Turning Point appeared first on InvestorPlace.
  • 10/01/2021

The Good News Is Piling Up for Cassava Stock

  • Recent news indicates that the FDA is going to reject a petition against Cassava, helping to make SAVA stock very attractive. The post The Good News Is Piling Up for Cassava Stock appeared first on InvestorPlace.
  • 10/01/2021

SAVA LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Cassava Sciences, Inc. Shareholders

  • New York, New York--(Newsfile Corp. - October 1, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/cassava-sciences-inc-loss-submission-form/?id=20034&from=5
  • 10/01/2021

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PHG, ATIP and SAVA

  • NEW YORK, NY / ACCESSWIRE / September 30, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
  • 09/30/2021

Cassava Shareholder Alert

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 30, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or...
  • 09/30/2021

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)

  • New York, New York--(Newsfile Corp. - September 30, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=20021&from=5
  • 09/30/2021

SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - September 30, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20016&wire=5
  • 09/30/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - September 30, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=20003&from=5
  • 09/30/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - September 30, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information go to:https://www.zlk.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19994&wire=5or...
  • 09/30/2021

Pomerantz Law Firm Announces the Filing of a Class Action Against Cassava Sciences, Inc. and Certain Officers - SAVA

  • NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and certain of its officers.
  • 09/29/2021

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VIEW, SAVA and HNST

  • NEW YORK, NY / ACCESSWIRE / September 29, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.
  • 09/29/2021

Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021

  • Philadelphia, Pennsylvania--(Newsfile Corp. - September 29, 2021) -  Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period"). If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please...
  • 09/29/2021

Cassava Sciences' Simufilam Could Be Approved Before The End Of 2022

  • Cassava Sciences Alzheimer's treatment has proven to not only slow down but also reverse cognition degeneration in Alzheimer's patients leaving the door open for early approval. Concerns existed on a possible placebo effect but recently presented 12-month data put those concerns aside and furthermore opened the door for FDA fast track approval or breakthrough designation.
  • 09/29/2021

SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - September 29, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19963&wire=5
  • 09/29/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - September 28, 2021) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19949&from=5
  • 09/28/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - September 28, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more...
  • 09/28/2021

SAVA INVESTOR LAWSUIT DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - September 28, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period"). The lawsuit filed in the United...
  • 09/28/2021

SAVA EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces that a Securities Fraud Class Action Lawsuit was filed on Behalf of Investors of Cassava Sciences, Inc.

  • RADNOR, Pa., Sept. 28, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces to investors that a securities fraud class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ:  SAVA) ("Cassava") on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021 , inclusive (the "Class Period").
  • 09/28/2021

SAVA INVESTOR FRAUD: Hagens Berman, National Trial Attorneys, Encourages Cassava Sciences (SAVA) Investors with $250K+ Losses to Contact Firm's Attorneys Now, Securities Fraud Lawsuit Filed

  • San Francisco, California--(Newsfile Corp. - September 28, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now. Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVAContact An Attorney Now: SAVA@hbsslaw.com844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and omissions concerning Casava's Alz
  • 09/28/2021

What's Happening With Cassava Sciences Stock?

  • Last month we discussed that Cassava Sciences stock, based on historical performance, is likely to see lower levels after it plunged 24% in a week following a citizen petition filed to halt the trials for Simufilam - Cassava's promising candidate for the treatment of Alzheimer's disease.
  • 09/28/2021

Is Cassava Sciences Back in the Game?

  • There's nothing spectacular about the latest results for the company's flagship drug.
  • 09/28/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - September 27, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19907&from=5
  • 09/27/2021

NATIONALLY RANKED ROSEN LAW FIRM Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important October 26 Deadline in Securities Class Action - SAVA

  • New York, New York--(Newsfile Corp. - September 27, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline.SO WHAT: If you purchased Cassava Sciences securities during the Class Period you may be entitled to compensation without payment of any out...
  • 09/27/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - September 27, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
  • 09/27/2021

Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021

  • Philadelphia, Pennsylvania--(Newsfile Corp. - September 27, 2021) - Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period"). If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please...
  • 09/27/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - September 26, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
  • 09/26/2021

(SAVA) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel Regarding Leading Cassava Sciences Class Action Lawsuit

  • SAN DIEGO, Sept. 25, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that purchasers of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, have until October 26, 2021, to file a lead plaintiff motion.
  • 09/25/2021

Cassava Update

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 25, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or options...
  • 09/25/2021

LAWSUITS FILED AGAINST OTLY, LIVE and SAVA - Jakubowitz Law Pursues Shareholders Claims

  • NEW YORK, NY / ACCESSWIRE / September 24, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.
  • 09/24/2021

Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021

  • Philadelphia, Pennsylvania--(Newsfile Corp. - September 24, 2021) - Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period"). If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please...
  • 09/24/2021

SAVA LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Cassava Sciences, Inc. Shareholders

  • New York, New York--(Newsfile Corp. - September 24, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/cassava-sciences-inc-loss-submission-form/?id=19844&from=5
  • 09/24/2021

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)

  • New York, New York--(Newsfile Corp. - September 23, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE: https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=19828&from=5
  • 09/23/2021

ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important October 26 Deadline in Securities Class Action - SAVA

  • NEW YORK, Sept. 23, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline.
  • 09/23/2021

Cassava Class Action Reminder

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 23, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or...
  • 09/23/2021

SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - September 23, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19811&wire=5
  • 09/23/2021

Why Shares of Cassava Sciences Rose 15% Today

  • Additional data is promising. But will investors trust it?
  • 09/23/2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences (SAVA) Investors with Losses in Excess of $250,000 to Contact Firm's Attorneys Now, Securities Fraud Class Action Filed

  • San Francisco, California--(Newsfile Corp. - September 23, 2021) -  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and omissions conc
  • 09/23/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - September 23, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and August 24, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19800&from=5
  • 09/23/2021

SAVA INVESTOR LAWSUIT DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.

  • NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period").
  • 09/23/2021

Cassava (SAVA) Posts Top-Line Data from AD Study on Simufilam

  • Cassava (SAVA) reports top-line data from an interim analysis of the on-going study evaluating simufilam in patients with mild-to-moderate Alzheimer's disease.
  • 09/23/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - September 23, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
  • 09/23/2021

MRM Stock: The Hair Salon Deal That has Holistic Healthcare Play Medirom All Lathered Up Today

  • Medirom Healthcare Technologies (MRM) stock is rocketing higher on Thursday following news of a major deal for the company. The post MRM Stock: The Hair Salon Deal That has Holistic Healthcare Play Medirom All Lathered Up Today appeared first on InvestorPlace.
  • 09/23/2021

Important Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit

  • Radnor, Pennsylvania--(Newsfile Corp. - September 22, 2021) -   The law firm of Kessler Topaz Meltzer & Check, LLP reminds Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who purchased or acquired Cassava securities during the Class Period may, no later...
  • 09/22/2021

SAVA: Berman Tabacco Alerts Investors with Losses Over $200,000 in Cassava Sciences, Inc. of Approaching Lead Plaintiff Deadline

  • Boston, Massachusetts--(Newsfile Corp. - September 22, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company. About the Securities Class Action FiledOn August 27, 2021, a securities class action complaint was filed in the Western District of Texas on behalf of purchasers of Cassava common stock between February 2, 2021 and August 24,...
  • 09/22/2021

Should you buy SAVA stock in Q4 2021 amid positive Simufilam trial data?

  • On Wednesday, Cassava Sciences Inc. (NASDAQ:SAVA) shares swang to a net intraday loss of about 3.52%, as of this writing, despite spiking more than 21% in the morning. The stock surged after the company posted top-line data on a pre-planned interim analysis of an ongoing open-label study with its drug label Simufilam in patients with […] The post Should you buy SAVA stock in Q4 2021 amid positive Simufilam trial data?
  • 09/22/2021

SAVA Stock: What Is Going on With Red-Hot Cassava Sciences Today?

  • Today, Cassava Sciences initially soared on the announcement of some positive preliminary data, before SAVA stock began selling off. The post SAVA Stock: What Is Going on With Red-Hot Cassava Sciences Today?
  • 09/22/2021

Cassava Sciences' Simufilam Data Shows Improved Cognition In Alzheimer's Disease

  • Cassava Sciences Inc (NASDAQ: SAVA) has announced top-line data from a pre-planned interim analysis of an ongoing open-label study of simufilam in mild-to-moderate Alzheimer's disease. Related Content:   Cassava CEO Goes Offensive Over Simufilam Data Allegations.
  • 09/22/2021

Cassava Sciences Announces Top-line Results of 12-month Interim Analysis from Open-label Study Evaluating Simufilam in Alzheimer's Disease

  • AUSTIN, Texas, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced top-line clinical data today from a pre-planned interim analysis of an on-going open-label study with its drug candidate simufilam in patients with mild-to-moderate Alzheimer's disease.
  • 09/22/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - September 21, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
  • 09/21/2021

Cassava Shareholder Alert

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 21, 2021) -  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or options...
  • 09/21/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

  • New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Cassava and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about...
  • 09/21/2021

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important October 26 Deadline in Securities Class Action - SAVA

  • New York, New York--(Newsfile Corp. - September 21, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline.SO WHAT: If you purchased Cassava Sciences securities during the Class Period you may be entitled to compensation without payment of any out of...
  • 09/21/2021

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Cassava Sciences, Inc. (SAVA) Investors and Encourages Investors to Contact the Firm Before October 26, 2021

  • NEW YORK--(BUSINESS WIRE)---- $SAVA--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Western District of Texas on behalf of those who acquired Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) securities from September 14, 2020 through August 27, 2021, inclusive (the “Class Period”). Investors have until October 26, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Cassava is a
  • 09/21/2021

Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021

  • Philadelphia, Pennsylvania--(Newsfile Corp. - September 21, 2021) -  Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period").If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please contact...
  • 09/21/2021

Cassava Sciences Can Recover Despite Harsh Allegations

  • SAVA stock dove after a law firm made statements against the company. However, Cassava's CEO isn't just taking it lying down.
  • 09/21/2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences (SAVA) Investors with Losses in Excess of $250,000 to Contact Firm's Attorneys Now, Securities Class Action Pending

  • San Francisco, California--(Newsfile Corp. - September 21, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and omissions concernin
  • 09/21/2021

The Curious Case Of Cassava Sciences

  • The Curious Case Of Cassava Sciences
  • 09/21/2021

Cassava Sciences: Medical History In The Making

  • Despite a sophisticated and highly profitable short attack, Cassava Sciences will commence two phase 3 trials shortly. Prior to October 1st, Cassava should release 12-month cognition data that we anticipate will be consistent with the 9-month data (ADAS-Cog11 range of -2.5 to -3.5+).
  • 09/21/2021

Cassava Sciences, Inc. (SAVA) Stock Moves -0.52%: What You Should Know

  • Cassava Sciences, Inc. (SAVA) closed at $48.26 in the latest trading session, marking a -0.52% move from the prior day.
  • 09/20/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - September 20, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and August 24, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19727&from=5
  • 09/20/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - September 20, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
  • 09/20/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

  • NEW YORK, Sept. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA).
  • 09/19/2021

SHAREHOLDER ALERT: ATVI ATIP SAVA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

  • NEW YORK, NY / ACCESSWIRE / September 19, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
  • 09/19/2021

Cassava Class Action Reminder

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 19, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or options...
  • 09/19/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - September 17, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more...
  • 09/17/2021

SAVA CLASS ACTION DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - September 17, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period"). The lawsuit filed in the United...
  • 09/17/2021

Cassava Sciences Has Value and Is Likely To Proceed to Phase 3

  • SAVA stock still has an implied upside of 67.9% to $78 per share, even if there is a 50% chance that either the shorts or longs are right. The post Cassava Sciences Has Value and Is Likely To Proceed to Phase 3 appeared first on InvestorPlace.
  • 09/17/2021

Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021

  • Philadelphia, Pennsylvania--(Newsfile Corp. - September 17, 2021) -  Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period"). If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please...
  • 09/17/2021

SHAREHOLDER ALERT: ITRM ATIP SAVA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

  • NEW YORK, NY / ACCESSWIRE / September 17, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
  • 09/17/2021

Cassava Shareholder Alert

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 16, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or...
  • 09/16/2021

Rosen, Global Investor Counsel, Encourages Cassava Sciences, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - SAVA

  • New York, New York--(Newsfile Corp. - September 16, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline.SO WHAT: If you purchased Cassava Sciences securities during the Class Period you may be entitled to compensation without payment of any out of...
  • 09/16/2021

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Cassava Sciences, Inc. (SAVA)

  • BENSALEM, Pa., Sept. 16, 2021 /PRNewswire/ -- Law Offices of Howard G.
  • 09/16/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - September 15, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and August 24, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA: https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19629&from=5.
  • 09/15/2021

Cassava Sciences: Is This Battleground Stock A Buy Or Sell As It Dips?

  • Few stocks with a market cap above a billion dollars display as much volatility as Cassava Sciences.
  • 09/15/2021

SAVA INVESTOR DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - September 15, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period"). The lawsuit filed in the United...
  • 09/15/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - September 15, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information go to:https://www.zlk.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19615&wire=5or...
  • 09/15/2021

SAVA LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Cassava Sciences, Inc. Shareholders

  • New York, New York--(Newsfile Corp. - September 14, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/cassava-sciences-inc-loss-submission-form/?id=19609&from=5
  • 09/14/2021

Class Action Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit

  • Radnor, Pennsylvania--(Newsfile Corp. - September 14, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who purchased or acquired Cassava securities during the Class Period may, no...
  • 09/14/2021

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)

  • New York, New York--(Newsfile Corp. - September 14, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=19596&from=5
  • 09/14/2021

SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - September 14, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19588&wire=5
  • 09/14/2021

Berman Tabacco Alerts Investors with Losses Over $200,000 in Cassava Sciences, Inc. (SAVA) of Approaching Lead Plaintiff Deadline

  • Boston, Massachusetts--(Newsfile Corp. - September 14, 2021) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company.About the Securities Class Action FiledOn August 27, 2021, a securities class action complaint was filed in the Western District of Texas on behalf of purchasers of Cassava common stock between February 2, 2021 and August 24, 2021, inclusive. ...
  • 09/14/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - September 14, 2021) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and August 24, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19577&from=5
  • 09/14/2021

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Cassava Sciences, Inc. (SAVA)

  • LOS ANGELES, Sept. 14, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming  October 26, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) securities between September 14, 2020 and August 27, 2021 , inclusive (the "Class Period").
  • 09/14/2021

INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

  • Los Angeles, California--(Newsfile Corp. - September 14, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
  • 09/14/2021

SAVA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Cassava Sciences, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm

  • New York, New York--(Newsfile Corp. - September 14, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Cassava securities between February 2, 2021 and August 24, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's...
  • 09/14/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - September 14, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information go to:https://www.zlk.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19565&wire=5or...
  • 09/14/2021

Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021

  • Philadelphia, Pennsylvania--(Newsfile Corp. - September 13, 2021) -  Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period"). If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please...
  • 09/13/2021

SAVA CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - September 13, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period"). The lawsuit filed in the United...
  • 09/13/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

  • NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA).
  • 09/13/2021

INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

  • Los Angeles, California--(Newsfile Corp. - September 13, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
  • 09/13/2021

CLASS ACTION UPDATE for OTLY, ANVS and SAVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

  • NEW YORK, NY / ACCESSWIRE / September 12, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.
  • 09/12/2021

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of QFIN, OTLY and SAVA

  • NEW YORK, NY / ACCESSWIRE / September 12, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
  • 09/12/2021

Cassava Shareholder Alert

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 12, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or options...
  • 09/12/2021

SAVA Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Cassava Sciences, Inc. of Deadline in Securities Fraud Class Action Lawsuit

  • RADNOR, Pa., Sept. 12, 2021 /PRNewswire/ -- September 12, 2021 – The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021 , inclusive (the "Class Period").
  • 09/12/2021

What Happens When A Biotech Stock Blows Up: How Our Hedged Portfolio Method Limited The Damage With Cassava Sciences

  • Screen capture via Cassava Sciences' video for their Simulfilam Alzheimer's disease treatment. When A Biotech Stock Goes The Wrong Way
  • 09/11/2021

SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - September 10, 2021) -  The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19505&wire=5
  • 09/10/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - September 10, 2021) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and August 24, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19494&from=5
  • 09/10/2021

SAVA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Cassava Sciences, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm

  • NEW YORK--(BUSINESS WIRE)--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Cassava securities between February 2, 2021 and August 24, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm's site: www.bgan
  • 09/10/2021

Do Options Traders Know Something About Cassava Sciences (SAVA) Stock We Don't?

  • Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
  • 09/10/2021

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

  • Los Angeles, California--(Newsfile Corp. - September 10, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
  • 09/10/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - September 9, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
  • 09/09/2021

Cassava Shareholder Alert

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 9, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or...
  • 09/09/2021

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

  • Los Angeles, California--(Newsfile Corp. - September 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
  • 09/09/2021

Cassava Sciences to Present at H.C. Wainwright's 23rd Annual Global Investment Conference

  • AUSTIN, Texas, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that management will present at H.C. Wainwright's 23rd Annual Global Investment Conference, a virtual event that takes place September 13-15, 2021.
  • 09/09/2021

Cassava Sciences Stock Still Poses Risks After Absorbing Data Controversy

  • Simufilam's eventual approval is still uncertain. Its fading popularity among the Reddit set is a concern as well.
  • 09/09/2021

7 Busted Biotech Stocks Due for a Rebound

  • Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on InvestorPlace.
  • 09/08/2021

Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit

  • Radnor, Pennsylvania--(Newsfile Corp. - September 8, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who purchased or acquired Cassava securities during the Class Period may, no...
  • 09/08/2021

Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021

  • Philadelphia, Pennsylvania--(Newsfile Corp. - September 8, 2021) - Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period"). If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please...
  • 09/08/2021

SAVA ALERT: Robbins Geller Rudman & Dowd LLP Announces Opportunity for Cassava Sciences, Inc. Investors with Substantial Losses to Lead the Case

  • San Diego, California--(Newsfile Corp. - September 7, 2021) - Robbins Geller Rudman & Dowd LLP filed a class action lawsuit charging Cassava Sciences, Inc. (NASDAQ: SAVA) and certain of its executives with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers or acquirers of Cassava Sciences securities between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"). The Cassava Sciences class action lawsuit is pending in the...
  • 09/07/2021

CASSAVA SCIENCES SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Cassava Sciences, Inc. - SAVA

  • NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 26, 2021 to file lead plaintiff applications in securities class action lawsuits against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive (the “Class Period”). These actions are pending in the United States District Co
  • 09/07/2021

HAGENS BERMAN Reminds Cassava Sciences, Inc. (SAVA) Investors of Securities Fraud Class Action, Encourages Investors with Losses to Contact Firm's Attorneys

  • San Francisco, California--(Newsfile Corp. - September 7, 2021) -  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and failed to discl
  • 09/07/2021

Berman Tabacco Alerts Investors with Losses Over $200,000 of Deadline for Seeking Appointment as Lead Plaintiff in Cassava Sciences, Inc. (SAVA)

  • Boston, Massachusetts--(Newsfile Corp. - September 7, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company. About the Securities Class Action FiledOn August 27, 2021, a securities class action complaint was filed in the Western District of Texas on behalf of purchasers of Cassava common stock between February 2, 2021 and August 24,...
  • 09/07/2021

INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

  • Los Angeles, California--(Newsfile Corp. - September 7, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
  • 09/07/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - September 6, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and August 24, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19416&from=5
  • 09/06/2021

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SAVA

  • NEW YORK, Sept. 6, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline.
  • 09/06/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - September 6, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
  • 09/06/2021

Rosen, A Top Ranked Law Firm, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SAVA

  • New York, New York--(Newsfile Corp. - September 5, 2021) -  WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no...
  • 09/05/2021

CLASS ACTION UPDATE for JRVR, YALA and SAVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

  • NEW YORK, NY / ACCESSWIRE / September 5, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.
  • 09/05/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

  • NEW YORK, Sept. 5, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA).
  • 09/05/2021

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc.

  • RADNOR, Pa.--(BUSINESS WIRE)---- $SAVA--Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc.
  • 09/04/2021

Better Buy: Biogen vs. Cassava Sciences

  • These two biotechs are going after a significant market: Alzheimer's.
  • 09/04/2021

Cassava Shareholder Alert

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 4, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or...
  • 09/04/2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors with Losses to Contact Firm's Attorneys Now, Securities Fraud Class Action Pending

  • San Francisco, California--(Newsfile Corp. - September 3, 2021) -  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading sta
  • 09/03/2021

INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

  • LOS ANGELES--(BUSINESS WIRE)---- $SAVA #SAVA--INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc.
  • 09/03/2021

SAVA DEADLINE: Berman Tabacco Alerts Investors with Losses In Excess of $200,000 of Deadline for Seeking Appointment as Lead Plaintiff in Cassava Sciences, Inc. Class Action

  • Boston, Massachusetts--(Newsfile Corp. - September 3, 2021) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company.About the Securities Class Action FiledOn August 27, 2021, a securities class action complaint was filed in the Western District of Texas on behalf of purchasers of Cassava common stock between February 2, 2021 and August 24, 2021, inclusive. ...
  • 09/03/2021

Cassava Sciences CEO says ‘enormous profit motive' behind N.Y. law firm's fraud allegations

  • Cassava Sciences Inc.'s Chief Executive Remi Barbier said on Friday that recent allegations of fraud were “false and misleading” and were a result of investor interests to drive down the price of the biotechnology company's stock.
  • 09/03/2021

Cassava CEO Goes Offensive Over Data Allegations

  • Cassava Sciences Inc (NASDAQ: SAVA) has garnered attention recently after a citizen petition with the FDA suggested that the use of Alzheimer's candidate data is based on manipulation and misrepresentation. Related:   Cassava Sciences Shares Sink With Alzheimer's Drug Mired In Controversy.
  • 09/03/2021

INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Investors

  • NEW YORK--(BUSINESS WIRE)---- $SAVA--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Western District of Texas on behalf of those who acquired Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) securities from September 14, 2020 through August 27, 2021, inclusive (the “Class Period”). Investors have until October 26, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Cassava is a clinical
  • 09/03/2021

Fraud Allegations Are Unlikely to Keep Cassava Stock Down

  • Cassava's unchallenged safety and cognition data will result in the FDA allowing it to conduct a Phase 3 trial. SAVA stock is a buy.
  • 09/03/2021

Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc. - SAVA

  • RADNOR, Pa., Sept. 3, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (NASDAQ:  SAVA) ("Cassava") on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021 , inclusive (the "Class Period").
  • 09/03/2021

Cassava Sciences Releases a Public Statement Regarding Recent Allegations

  • AUSTIN, Texas, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today released a public statement regarding recent allegations made against the Company.
  • 09/03/2021

Cassava Shareholder Alert

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 2, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or...
  • 09/02/2021

SAVA Lawsuit Filed: Jakubowitz Law Pursues Claims on Behalf of Cassava Sciences, Inc. Shareholders

  • New York, New York--(Newsfile Corp. - September 2, 2021) -  Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/cassava-sciences-inc-loss-submission-form/?id=19314&from=5
  • 09/02/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

  • New York, New York--(Newsfile Corp. - September 2, 2021) -  Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Cassava and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
  • 09/02/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - September 2, 2021) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and August 24, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19306&from=5
  • 09/02/2021

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Cassava Sciences, Inc. (SAVA)

  • BENSALEM, Pa.--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Law Offices of Howard G. Smith reminds investors of the upcoming October 26, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) securities between September 14, 2020 and August 27, 2021, inclusive (the “Class Period”). Investors suffering losses on their Cassava investments are encouraged to contact the Law Offices of Howard G. Smith to discuss the
  • 09/02/2021

SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - September 2, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19295&wire=5
  • 09/02/2021

Cassava Sciences Stock Will Fall Further on Data Manipulation Allegations

  • SAVA stock is still one of the best performers this year, but the recent allegations mean shares will fall further as the story develops. The post Cassava Sciences Stock Will Fall Further on Data Manipulation Allegations appeared first on InvestorPlace.
  • 09/02/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - September 1, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more...
  • 09/01/2021

SAVA ALERT: Berman Tabacco Announces Approaching Lead Plaintiff Deadline for Cassava Sciences, Inc. Investors with Losses in Excess of $100,000

  • Boston, Massachusetts--(Newsfile Corp. - September 1, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company.About the Securities Class Action FiledOn August 27, 2021, a securities class action complaint was filed in the Western District of Texas on behalf of purchasers of Cassava common stock between February 2, 2021 and August 24, 2021, inclusive...
  • 09/01/2021

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)

  • New York, New York--(Newsfile Corp. - September 1, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=19247&from=5
  • 09/01/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - September 1, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and August 24, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19239&from=5
  • 09/01/2021

SAVA INVESTOR ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - September 1, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period"). The lawsuit filed in the United...
  • 09/01/2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors with Losses to Contact Firm's Attorneys Now, Securities Fraud Class Period Expanded

  • SAN FRANCISCO, Sept. 1, 2021 /PRNewswire/ -- Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.
  • 09/01/2021

SAVA ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cassava Sciences, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case

  • SAN DIEGO--(BUSINESS WIRE)-- #Cassavacase--The suit alleges defendants issued false statements concerning Cassava business and prospects, resulting in its stock trading at inflated prices.
  • 08/31/2021

SHAREHOLDER ALERT: Robbins LLP Announces that Cassava Sciences, Inc. (SAVA) is Being Sued for Misleading Shareholders

  • SAN DIEGO & AUSTIN, Texas--(BUSINESS WIRE)---- $SAVA #LawFirm--Shareholder rights law firm Robbins LLP announces that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Cassava Sciences, Inc. (NASDAQ: SAVA) securities between February 2, 2021 and August 24, 2021, for violations of the Securities Exchange Act of 1934. Cassava is a biotechnology company engaged in the development of drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simuf
  • 08/31/2021

Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021

  • Philadelphia, Pennsylvania--(Newsfile Corp. - August 31, 2021) - Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period"). If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests,...
  • 08/31/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - August 31, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more...
  • 08/31/2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors to Contact Firm's Attorneys Now, Securities Fraud Class Period Expanded

  • San Francisco, California--(Newsfile Corp. - August 31, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and failed to...
  • 08/31/2021

SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - August 31, 2021) -  The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19189&wire=5
  • 08/31/2021

SAVA INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc.

  • NEW YORK, Aug. 31, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (Nasdaq: SAVA) from February 2, 2021 through August 24, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Western District of Texas alleges violations of the Securities Act of 1934.
  • 08/31/2021

LAWSUIT FILED - Expanded Class Period: CASSAVA SCIENCES Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

  • Boston, Massachusetts--(Newsfile Corp. - August 31, 2021) -  Block & Leviton announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) for potential securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/sava.What is this all about?On August 24, 2021, after market hours, Cassava Sciences stock dropped over...
  • 08/31/2021

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Investors

  • LOS ANGELES--(BUSINESS WIRE)---- $SAVA #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Investors
  • 08/31/2021

Short sellers betting against meme stock Cassava have made $100 million over the past month as the stock has struggled

  • Short sellers have raked in millions betting against drugmaker and meme stock Cassava Sciences. But some retail investors say they're buying the dip.
  • 08/31/2021

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Investors

  • BENSALEM, Pa.--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) securities between September 14, 2020 and August 27, 2021, inclusive (the “Class Period”). Cassava investors have until October 26, 2021 to file a lead plaintiff motion. Investors suffering losses on their Cassava investments are encouraged to contact the Law Offices of Howard G
  • 08/31/2021

Wait to See How the Cassava Sciences Allegations Pan Out

  • Allegations have been leveled against Cassava Sciences. SAVA stock has fallen by more than 50% as a result.
  • 08/31/2021

SAVA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Cassava Sciences, Inc. Investors of Class Action and Encourages Investors to Contact the Firm

  • NEW YORK, Aug. 31, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company")  NASDAQ: SAVA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Cassava securities between February 2, 2021 and August 24, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/sava.
  • 08/31/2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors to Contact Firm's Attorneys Now, Securities Fraud Case Filed

  • SAN FRANCISCO, Aug. 31, 2021 /PRNewswire/ -- Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.     Class Period: Feb. 2, 2021 – Aug. 24, 2021 Lead Plaintiff Deadline: Oct. 26, 2021 Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com                                                844-916-0895 Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Cassava and senior management made false and misleading statements and failed to disclose that the quality and integrity of the scientific data supporting the company's claims of efficacy for its Alzheimer's drug (simufilam) were overstated and biased.
  • 08/31/2021

Scrutiny Makes Cassava Sciences Stock a ‘Blood in the Street' Opportunity

  • Cassava Sciences stock crashed after a lawyer sought to stop studies of the biotech's experimental Alzheimer's treatment. That just makes SAVA stock a better opportunity.
  • 08/31/2021

SAVA DEADLINE: Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cassava Sciences, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case

  • SAN DIEGO, Aug. 30, 2021 /PRNewswire/ --  Robbins Geller Rudman & Dowd LLP announces that it filed a class action lawsuit charging Cassava Sciences, Inc. (NASDAQ: SAVA) and certain of its executives with violations of the Securities Exchange Act of 1934.  Purchasers of Cassava Sciences common stock between February 2, 2021 and August 24, 2021, inclusive (the "Class Period") have until October 26, 2021 to seek appointment as lead plaintiff in the Cassava Sciences class action lawsuit.
  • 08/30/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - August 30, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and August 24, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19158&from=5
  • 08/30/2021

CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cassava Sciences and Encourages Investors to Contact the Firm

  • NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) in the United States District Court for the Western District of Texas on behalf of all persons and entities who purchased or otherwise acquired Cassava securities between February 2, 2021 and August 24, 2021, both dates inclusive (the “Class Period”). Invest
  • 08/30/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - August 30, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
  • 08/30/2021

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

  • LOS ANGELES--(BUSINESS WIRE)---- $SAVA #SAVA--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc.
  • 08/30/2021

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important Deadline – SAVA

  • NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 26, 2021. SO WHAT: If you purchased Cassava Sciences securities during the
  • 08/30/2021

Cassava Sciences Is on the Ropes, so Watch for a Dip-Buy Opportunity

  • Amid a regulatory tug-of-war over a proposed Alzheimer's disease treatment, SAVA stock has become a speculator's playground. The post Cassava Sciences Is on the Ropes, so Watch for a Dip-Buy Opportunity appeared first on InvestorPlace.
  • 08/30/2021

CLASS ACTION UPDATE for LOTZ, CRMD and SAVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

  • NEW YORK, NY / ACCESSWIRE / August 30, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.
  • 08/30/2021

Cassava Sciences And Alzheimer's Disease: Raising Doubts

  • On behalf of a whistleblower or whistleblowers, the law firm of Labaton Sucharow has asked the FDA to halt Cassava Sciences' clinical trials on the basis of potential data manipulation. Perhaps the whistleblower's most serious charge is that Cassava Sciences turned to its own affiliated lab to overcome poor results reported by an independent lab.
  • 08/29/2021

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SRAC, BLCT and SAVA

  • NEW YORK, NY / ACCESSWIRE / August 29, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
  • 08/29/2021

SHAREHOLDER ALERT: CRMD ATIP SAVA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

  • NEW YORK, NY / ACCESSWIRE / August 29, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
  • 08/29/2021

Cassava Update

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 29, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA).If you suffered losses exceeding $50,000 investing in Cassava stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information:...
  • 08/29/2021

SAVA ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cassava Sciences, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case

  • SAN DIEGO--(BUSINESS WIRE)-- #Cassavacase--The suit alleges defendants issued false statements concerning Cassava business and prospects, resulting in its stock trading at inflated prices.
  • 08/28/2021

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

  • LOS ANGELES--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Cassava investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your
  • 08/27/2021

The Law Offices of Frank R. Cruz Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

  • LOS ANGELES--(BUSINESS WIRE)---- $SAVA #investors--The Law Offices of Frank R. Cruz Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
  • 08/27/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - August 27, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
  • 08/27/2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations

  • San Francisco, California--(Newsfile Corp. - August 27, 2021) -  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Investigation: The investigation focuses on whether Cassava misled investors about the integrity of preliminary analysis of a small clinical trial of the company's Alzheimer's drug, simufilam. On July 29, 2021 Cassava...
  • 08/27/2021

Cassava Sciences punches back, after Qaunterix took a swing by saying it didn't interpret or prepare the disputed trial data

  • Quanterix Corp. took a swing at Cassava Sciences Inc. Friday, but then Cassava hit back, stressing that Quanterix was contracted to perform sample testing of the trial data that have been disputed.
  • 08/27/2021

SAVA: Berman Tabacco Alerts Investors with Losses of $100,000 from Investments in Cassava Sciences, Inc. of Deadline to Apply to Serve as Lead Plaintiff

  • Boston, Massachusetts--(Newsfile Corp. - August 27, 2021) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company. If you sustained losses in excess of $100,000 from your transactions in Cassava securities during the Class Period and are interested in learning more about serving as Lead Plaintiff, please provide your information here: Shareholder Contact |...
  • 08/27/2021

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

  • BENSALEM, Pa.--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Law Offices of Howard G. Smith continues its investigation on behalf of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) investors concerning the Company's possible violations of federal securities laws. On August 24, 2021, after the market closed, it was revealed that a Citizen Petition was filed with the United States Food and Drug Administration (“FDA”) requesting that the FDA halt two ongoing trials of Cassava's proprietary drug Simufilam. T
  • 08/27/2021

SAVA NOTICE: Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cassava Sciences, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case

  • SAN DIEGO, Aug. 27, 2021 /PRNewswire/ --  Robbins Geller Rudman & Dowd LLP today announced that it filed a class action lawsuit charging Cassava Sciences, Inc. (NASDAQ: SAVA) and certain of its executives with violations of the Securities Exchange Act of 1934 and seeking to represent purchasers of Cassava Sciences common stock between February 2, 2021 and August 24, 2021, inclusive (the "Class Period").  The Cassava Sciences class action lawsuit was commenced on August 27, 2021 in the Western District of Texas and is captioned Brazeau v.
  • 08/27/2021

Why the Cassava Sciences Bears Are Wrong

  • The stock's been a wild ride for investors all year, and it's dropped more than 50% in two days. What's going on, and why am I bullish?
  • 08/27/2021

Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer's Patients

  • AUSTIN, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today released a statement regarding plasma p-tau analysis from a previously disclosed randomized, controlled Phase 2b clinical study in patients with Alzheimer's disease. For this study, Cassava Sciences contracted with Quanterix Corp., a highly regarded, independent laboratory, to perform sample testing on blinded samples.
  • 08/27/2021

Ongoing Investigation Alert: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm

  • LOS ANGELES, Aug. 27, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • 08/27/2021

Why Cassava Sciences Is Plunging Again Today

  • More red flags are emerging for this troubled Alzheimer's biotech company.
  • 08/27/2021

Why Cassava Sciences Stock Investors Are Pulling Back

  • The neurodegenerative diseases-focused biopharma Cassava Sciences, Inc. (NASDAQ: SAVA) has now lost half of its market capitalization.  What Happened: Cassava shares plunged Wednesday in reaction to a citizen petition calling for halting clinical studies of its lead drug candidate simufilam due to alleged data manipulation and misrepresentation.
  • 08/27/2021

Which Biotech Stock Will Shock the Market in 2022?

  • Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?
  • 08/27/2021

Cassava's stock tumbles again, after Quanterix said it 'did not' prepare data charts presented by Cassava, that are under dispute

  • Quanterix Corp. QTRX, -9.21% said that while it was previously engaged by Cassava Sciences Inc. SAVA, -12.38% to perform sample testing, the digitized biomarker analysis company said it, or its employees, "did not interpret the test results or prepare the data charts" presented by Cassava to the Alzheimer's Association International Conference (AAIC) in July, or otherwise. Earlier this week, in Cassava's response to a request the Food and Drug Administration halt clinical studies of Cassava's Alzheimer's treatment because of concerns over the accuracy and integrity of presented biomarker data, Cassava had said that data from Alzheimer's patients were generated by Quanterix.
  • 08/27/2021

Specious Claims And Spurious Accusations Are All The Bears Can Muster Against Cassava Sciences

  • The petition filed against Cassava Sciences is so misleading and wrong-headed it seems an intentional act of FUD and not a serious request.
  • 08/27/2021

After A 30% Fall Cassava Stock Is Likely To See Lower Levels

  • The stock price of Cassava Sciences, a clinical stage biotechnology company focused on treatment for Alzheimer's disease, has seen a large 31% decline in a single trading session on Aug 25. SAVA stock has had a volatile ride over the last year or so, and despite yesterday's fall, the stock is.
  • 08/27/2021

CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences on Behalf of Cassava Sciences Stockholders and Encourages Investors to Contact the Firm

  • NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (“Cassava Sciences” or the “Company”) (NASDAQ: SAVA) on behalf of Cassava Sciences stockholders. Our investigation concerns whether Cassava Sciences has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On August 24, 2021, after the market
  • 08/26/2021

Cassava Shareholder Alert

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 26, 2021) -  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA).If you suffered losses exceeding $50,000 investing in Cassava stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information:...
  • 08/26/2021

SAVA Alert: Berman Tabacco Investigates Cassava Sciences, Inc. for Potential Securities Claims in Connection with FDA Citizen Petition

  • Boston, Massachusetts--(Newsfile Corp. - August 26, 2021) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company.On August 25, 2021, Bloomberg reported that shares of Cassava were down 31% "after a lawyer sought to stop studies of the biotech company's experimental treatment for Alzheimer's disease." According to Bloomberg, "a citizen petition from a former Securities...
  • 08/26/2021

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm

  • LOS ANGELES--(BUSINESS WIRE)---- $SAVA #SAVA--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc.
  • 08/26/2021

Cassava Sciences Likely To Survive Latest Attack On Alzheimer's Drug, But Caveat Emptor

  • Cassava has received the go-ahead from the FDA to initiate two pivotal trials of its Alzheimer's therapy Simufilam. One week ago, however, a citizen's petition filed with the FDA insisted that data from earlier studies of Simufilam had been manipulated in various ways.
  • 08/26/2021

Why Traders Shouldn't Bargain Hunt in Cassava Stock

  • Wall Street is notorious for its overreactions, but when it comes to SAVA stock's cratering, investors consider other historical precedents. The post Why Traders Shouldn't Bargain Hunt in Cassava Stock appeared first on InvestorPlace.
  • 08/26/2021

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Inquire About Class Action Investigation – SAVA

  • NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) resulting from allegations that Cassava Sciences may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Cassava Sciences securities you may be entitled to compensation without payment of any out of pocket fees or costs through a conting
  • 08/26/2021

As Allegations Swirl, Can Investors Still Count on Cassava Sciences Stock?

  • This once-promising biotech is now struggling to stay afloat.
  • 08/26/2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations

  • SAN FRANCISCO, Aug. 26, 2021 /PRNewswire/ -- Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.     Visit: www.hbsslaw.com/investor-fraud/SAVA  Contact An Attorney Now: SAVA@hbsslaw.com                                                844-916-0895 Cassava Sciences, Inc. (SAVA) Investigation: The investigation focuses on whether Cassava misled investors about the integrity of preliminary analysis of a small clinical trial of the company's Alzheimer's drug, simufilam.
  • 08/26/2021

Biotech Stock Tries to Recover as Alzheimer's Drug Draws Questions

  • Cassava Sciences Inc (NASDAQ:SAVA) is up 4.1% at $84.16 this morning, in an attempt to bounce back from yesterday's news that its Alzheimer's drug was facing scrutiny.
  • 08/26/2021

Better Biotech Stock: Cassava Sciences vs. Annovis Bio

  • It boils down to which company's clinical trial results look better for treating Alzheimer's at the moment.
  • 08/26/2021

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm

  • LOS ANGELES--(BUSINESS WIRE)---- $SAVA #SAVA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc.
  • 08/25/2021

Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

  • LOS ANGELES--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) investors concerning the Company and its officers' possible violations of the federal securities laws. If you suffered a loss on your Cassava investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit
  • 08/25/2021

Cassava Investor Alert

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 25, 2021) -  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA).If you suffered losses exceeding $50,000 investing in Cassava stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information:...
  • 08/25/2021

The Law Offices of Frank R. Cruz Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

  • LOS ANGELES--(BUSINESS WIRE)---- $SAVA #investors--The Law Offices of Frank R. Cruz Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
  • 08/25/2021

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

  • BENSALEM, Pa.--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Law Offices of Howard G. Smith continues its investigation on behalf of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) investors concerning the Company and its officers' possible violations of federal securities laws. On August 24, 2021, after the market closed, it was revealed that a Citizen Petition was filed with the United States Food and Drug Administration (“FDA”) requesting that the FDA halt two ongoing trials of Cassava's proprietary d
  • 08/25/2021

SAVA Stock: Cassava Sciences Sinks Despite Countering Trial Data Allegations

  • Today, investors in Cassava Sciences and SAVA stock are seeing a lot of red, as investors digest a statement of concern filed yesterday. The post SAVA Stock: Cassava Sciences Sinks Despite Countering Trial Data Allegations appeared first on InvestorPlace.
  • 08/25/2021

SHAREHOLDER ALERT: Investigation of Cassava Sciences, Inc. Announced by Holzer & Holzer, LLC

  • Atlanta, Georgia--(Newsfile Corp. - August 25, 2021) - Holzer & Holzer, LLC is investigating whether Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) complied with federal securities laws. On August 24, 2021, it was revealed that a Citizen Petition had been filed with the FDA, questioning the quality and integrity of the Company's research and data, suggesting the data had been manipulated. The Petition further sought a halt to Cassava's current clinical...
  • 08/25/2021

2 Little-Known Nasdaq Stocks Making Big Moves Wednesday

  • Don't let these companies fly under your radar.
  • 08/25/2021

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

  • LOS ANGELES--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Cassava investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securitie
  • 08/25/2021

Shareholder Alert: Berman Tabacco Announces Investigation of Cassava Sciences, Inc. (SAVA) for Potential Securities Law Violations

  • Boston, Massachusetts--(Newsfile Corp. - August 25, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company. On August 25, 2021, Bloomberg reported that shares of Cassava were down over 20% in pre-market trading "after a lawyer asked the FDA to halt the company's clinical trials of an experimental drug, citing concerns about the...
  • 08/25/2021

7 Bargain Stocks to Buy Under $5 With the Right Catalysts

  • The risk in these inexpensive bargain stocks is offset by their upside for investors looking for a little more spice in their portfolio. The post 7 Bargain Stocks to Buy Under $5 With the Right Catalysts appeared first on InvestorPlace.
  • 08/25/2021

Here's why Cassava Sciences stock tanked 30% Wednesday morning

  • Cassava Sciences Inc (NASDAQ: SAVA) reached an SPA (Special Protocol Assessment) agreement with the U.S. FDA on Tuesday morning for the phase 3 trial of its Alzheimer's treatment, Simufilam. Shares of the company, however, tanked about 30% this morning on a statement of concern that raised a question on the integrity of western blot analyses […] The post Here's why Cassava Sciences stock tanked 30% Wednesday morning appeared first on Invezz.
  • 08/25/2021

Cassava Sciences Stock Shows Promise With Simufilam Trials Drawing Near

  • SAVA stock is up as the company announced the FDA has agreed on study protocols for Phase 3 clinical trials of Simufilam. The post Cassava Sciences Stock Shows Promise With Simufilam Trials Drawing Near appeared first on InvestorPlace.
  • 08/25/2021

Cassava Sciences Shares Sink With Alzheimer's Drug Mired In Controversy

  • Neurodegenerative diseases-focused biopharma Cassava Sciences, Inc. (NASDAQ: SAVA) saw both sides of the world Tuesday. The stock rallied to close higher by 2% after it announced an agreement with the Food and Drug Administration regarding two late-stage studies of its lead drug candidate simufilam in Alzheimer's disease.
  • 08/25/2021

Why Cassava Sciences' Stock Is Getting Hammered Today

  • Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading lower on negative claims that were posted online yesterday after market hours. The company issued a response to the claims today, saying they believe the claims regarding scientific integrity are false and misleading.
  • 08/25/2021

SAVA Stock: Over 20% Decrease Pre-Market Explanation

  • The stock price of Cassava Sciences Inc (NASDAQ: SAVA) fell by over 20% pre-market. This is why it happened.
  • 08/25/2021

Cassava Sciences stock tumbles, and company responds to allegations disputing trial data

  • Cassava Sciences Inc. SAVA, +1.92% responded Wednesday to allegations posted overnight regarding the "accuracy and integrity" of trial data for its treatment of Alzheimer's disease, saying it believed the claims are "false and misleading." Cassava's stock had rallied 1.9% on Tuesday, and 16.4% over the past three days, with the company saying early Tuesday that it reached agreement with the Food and Drug Administration under a Special Protocol Assessment (SPA) for its Phase 3 studies of oral simufilam for the treatment of Alzheimer's patients.
  • 08/25/2021

Cassava Sciences Responds to Allegations

  • AUSTIN, Texas, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today issued a response to claims that were posted on-line yesterday after market hours. Cassava Sciences believes the claims made in this post regarding scientific integrity are false and misleading. The Company stands behind its science, its scientists and its scientific collaborators, and is responding to ensure the facts are known and respected.
  • 08/25/2021

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

  • BENSALEM, Pa.--(BUSINESS WIRE)---- $SAVA #ClassAction--Law Offices of Howard G. Smith Announces Investigation of Cassava Sciences, Inc. (SAVA)
  • 08/25/2021

Cassava Sciences Has an Admirable Goal at Too High a Price

  • It would be great if Cassava Sciences' treatment for Alzheimer's disease worked, but should you pay the high price for SAVA stock? No. The post Cassava Sciences Has an Admirable Goal at Too High a Price appeared first on InvestorPlace.
  • 08/24/2021

5 Penny Stocks That Turned $2,500 Into Over $29,000 In 2021 So Far

  • Hot Penny Stocks That Scored Huge For Traders In 2021 The post 5 Penny Stocks That Turned $2,500 Into Over $29,000 In 2021 So Far appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 08/24/2021

Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer's Disease

  • Phase 3 Study Initiation Still Expected Fall 2021 Phase 3 Study Initiation Still Expected Fall 2021
  • 08/24/2021

Soaring Cassava Sciences Stock Shows Unfettered Promise for Growth

  • With more than 6 million people in the U.S. suffering from Alzheimer's disease, SAVA stock has enormous potential for future profits. The post Soaring Cassava Sciences Stock Shows Unfettered Promise for Growth appeared first on InvestorPlace.
  • 08/20/2021

Cassava Sciences Stock Has Had an Epic Run, but Getting in Now Is a Serious Risk

  • Given it's at risk of a severe pullback if it stumbles going forward? If you own, take some risk off the table, by partially paring down your position.
  • 08/19/2021

These Are the Top Reasons You Should Load Up on Cassava Sciences Stock

  • At the moment, there's no cure for Alzheimer's, but Cassava Sciences is working to wipe it out for good making SAVA stock a buy here. The post These Are the Top Reasons You Should Load Up on Cassava Sciences Stock appeared first on InvestorPlace.
  • 08/18/2021

With This Exciting Alzheimer's Treatment, Cassava Sciences Stock Has Legs

  • Incredible Alzheimer's data suggests that Cassava has the right approach to tackling the disease powering SAVA stock The post With This Exciting Alzheimer's Treatment, Cassava Sciences Stock Has Legs appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America's #1 EV Stock Still Flying Under the Radar
  • 08/16/2021

Cassaca Sciences Stock Is a Buy on the Strength of a Promising Alzheimer's Drug

  • Skeptics are wrong about Cassava's Alzheimer's drug, as the drug's data is superb. Long-term investors should buy SAVA stock.
  • 08/16/2021

Why Might Cassava Succeed With Its Alzheimer's Drug, When So Many Have Failed?

  • Alzheimer's research has been hampered by apparently mistaken ideas about what causes the disease. Cassava has a new theory about what's responsible -- and its drug is showing positive results.
  • 08/14/2021

Analyzing the Potential Risks of Cassava Sciences

  • Cassava Sciences has a promising drug candidate for Alzheimer's. However, SAVA stock may be overpriced based on the limited data so far.
  • 08/13/2021

Why Is Cassava Sciences' Stock So Volatile?

  • The stock is up 1,700% year to date.
  • 08/12/2021

Cassava Sciences vs. Biogen

  • Who will emerge victorious in the race to help Alzheimer's patients?
  • 08/12/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

  • NEW YORK, Aug. 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Robert S.
  • 08/11/2021

Here's What Investors Should Know About Cassava's Alzheimer's Drug Candidate

  • Cassava believes that a mutating protein, Filamin A, is a major culprit behind Alzheimer's disease. The company's drug, simufilam, aims to fix this mutation and restore its proper form and function.
  • 08/11/2021

Bring a Neck Brace When Trading Cassava Sciences

  • Cassava is still pre-revenue but SAVA stock has a flock of strong fans. They bought the dip with gumption, which suggests long-term success.
  • 08/11/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

  • New York, New York--(Newsfile Corp. - August 9, 2021) -  Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Cassava and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
  • 08/09/2021

Why Shares of Cassava Sciences Fell 18.6% in July

  • The stock lost $75 a share in two days at the end of the month.
  • 08/09/2021

What to Do After Cassava Sciences Dropped Off a Cliff

  • Cassava Sciences posted positive clinical data but triggered a sell on the news event, as SAVA stock short sellers welcomed the drop. The post What to Do After Cassava Sciences Dropped Off a Cliff appeared first on InvestorPlace.
  • 08/09/2021

Cassava Sciences May Be Revolutionary in the Alzheimer's Fight

  • SAVA stock is truly worth paying attention to from here forward as data suggests Cassava Sciences may have solved a big mystery. The post Cassava Sciences May Be Revolutionary in the Alzheimer's Fight appeared first on InvestorPlace.
  • 08/05/2021

Are Penny Stocks Worth It? 5 That Deserve Your Attention Now

  • Have penny stocks presented some of the biggest opportunities in the stock market? The post Are Penny Stocks Worth It?
  • 08/05/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

  • NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Robert S.
  • 08/03/2021

Detours In The Golden Age Of Alzheimer's Drug Stock Investments

  • Biogen's Aduhelm performed no better than placebo in non-ApoE4 carriers and only slightly slowed down the progression of Alzheimer's disease in ApoE4 carriers.
  • 08/03/2021

SAVA Stock Price Increases Over 17% Intraday: Why It Happened

  • The stock price of Cassava Sciences Inc (NASDAQ: SAVA) increased by over 17% during intraday trading. This is why it happened.
  • 08/03/2021

Cassava Sciences Stock Has Been Hammered For No Good Reason and Is Likely To Rebound

  • Cassava Sciences stock has been hammered for no good reason and is likely to rebound. AVA stock is still worth over $900 especially given the recent positive 9-month results of its Alzheimer's drug Simufilam.
  • 08/03/2021

Why Former NYSE Trader David Green Bought NVIDIA, Tesla, and Cassava Sciences On Tuesday

  • Veteran trader David Green was back live trading on Benzinga Tuesday morning, and the long-time trader made some moves.  Green pointed out the strength of NVIDIA Corporation (NASDAQ:NVDA) Tuesday morning.
  • 08/03/2021

Cassava Sciences Reports Second Quarter 2021 Financial Results

  • - Conference Call Today at 9 a.m. ET - - Conference Call Today at 9 a.m. ET -
  • 08/03/2021

5 Ultra-Popular Stocks to Avoid Like the Plague in August

  • These stocks look to be more trouble than they're worth.
  • 08/03/2021

Cassava Sciences Announces Conference Call for Second Quarter Financial Results

  • - Call-in on Tuesday, August 3rd at 9 a.m. ET - - Call-in on Tuesday, August 3rd at 9 a.m. ET -
  • 08/02/2021

Cassava Sciences' Simufilam Is The First Alzheimer's Drug To Work At 9 Months, And The Benefit Is Growing

  • Simufilam is the first AD drug to show a cognitive improvement at 9 months, with a gaudy 18% mean improvement from baseline. Simufilam also showed a growing behavioral benefit.
  • 07/30/2021

SAVA Stock Fell 23.61%: Details You Should Know

  • The stock price of Cassava Sciences Inc (NASDAQ: SAVA) fell by over 25% during intraday trading. These are some details you should know.
  • 07/29/2021

Cassava Sciences Stock Has Plenty of Momentum After Positive Clinical Data

  • As Cassava Sciences made progress in treating Alzheimer's, SAVA stock is on a powerful path to significantly higher prices. The post Cassava Sciences Stock Has Plenty of Momentum After Positive Clinical Data appeared first on InvestorPlace.
  • 07/29/2021

Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday

  • A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.
  • 07/29/2021

Should You Invest in This Seemingly Unstoppable Alzheimer's Biotech?

  • This popular life science company has a fair but risky shot of developing a novel drug to treat Alzheimer's disease.
  • 07/29/2021

Cassava Sciences: Critical Alzheimer's Data Due Thursday Offers Upside Potential

  • Cassava Sciences shares are +3,300% in the past year, but the upside could continue until the $4.5bn market cap biotech achieves a >$50bn valuation.
  • 07/27/2021

Cassava Sciences Stock Could Be Worth $900 After Its Upcoming Alzheimer's Results

  • Cassava Sciences stock could jump with its upcoming Alzheimer's results. SAVA stock options show the lofty expectations investors have.
  • 07/23/2021

An Unforgettable Week For Alzheimer's Treatment Stocks: Two Of Our Recent Top Names Spike On News Of Potentially Promising Treatments

  • Screen capture via IGC's healthcare subsidiary Hyalolex. "Drops of Clarity" is their just-patented Alzheimer's treatment.
  • 07/23/2021

Cassava Sciences Stock Soars In Anticipation Of Alzheimer's Data: A Technical Analysis

  • On Thursday, Cassava Sciences, Inc (NASDAQ: SAVA) smashed through a resistance level at $117.54, made 21 years ago between its initial public offering date of June 14, 2000 and December of that year. On Wednesday, the biopharmaceutical company announced it will present new clinical-trial data from a Phase 2 trial of its drug simufilam at the Alzheimer's Association International Conference (AAIC) on July 29.
  • 07/22/2021

Cassava Sciences stock price forecast for Q3 after shares rally 27%

  • Meme stock Cassava Sciences Inc. (NASDAQ:SAVA) shares surged more than 27% on Wednesday after revealing plans to present data on its Alzheimer's drug, Simufilam, on 29th July. Cassava will read out its interim analysis on a 9-month treatment with Simulflam at the 2021 Alzheimer's Association International Conference (AAIC) in Denver.
  • 07/21/2021

Here's Why Cassava Sciences Is Surging Today

  • Investors are excited about upcoming presentations scheduled for the annual Alzheimer's Association International Conference.
  • 07/21/2021

SAVA Stock: Two Dates Cassava Investors Need to Mark on Their Calendars

  • SAVA stock is flying upward today as investors clamor to hear information around two new products. Investors should save two upcoming dates.
  • 07/21/2021

SAVA Stock Increases Over 33% Intraday: Why It Happened

  • The stock price of Cassava Sciences Inc (Nasdaq: SAVA) increased by over 33% during intraday trading. This is why it happened.
  • 07/21/2021

3 Biotech Penny Stocks To Watch Seeing Explosive Gains In 2021

  • Are biotech penny stocks on your watch list in 2021? The post 3 Biotech Penny Stocks To Watch Seeing Explosive Gains In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 07/21/2021

Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer's Association International Conference

  • - On Monday, July 26 th , New Clinical Data for SavaDx to be Shared in a Poster Presentation -
  • 07/21/2021

Here's Why Cassava Sciences Is Up 1,152% in the First Half of 2021

  • This small-cap biotech has shot up in value as the company's Alzheimer's drug makes it way through clinical trials.
  • 07/20/2021

Why Is Cassava Sciences Stock Soaring in 2021?

  • The stock market is excited by the clinical trial results for its Alzheimer's drug.
  • 07/20/2021

Cassava Sciences Is On The Brink Of Making Medical History

  • Cassava is dramatically undervalued.
  • 07/20/2021

Cassava Sciences (SAVA) to Post Q2 Earnings: What's in Store?

  • Investors will be keen on updates from on its lead candidate, sumifilam, for Alzheimer's disease when Cassava (SAVA) reports Q2 results.
  • 07/16/2021

Why Cassava Sciences Stock Moved Higher Monday

  • The biotech stock bounced back big Monday after tumbling on Friday.
  • 07/12/2021

7 Top-Rated Pharmaceutical Companies to Invest In for July

  • Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest In for July appeared first on InvestorPlace.
  • 07/09/2021

Anavex: A Catalyst-Rich Year

  • Anavex: A Catalyst-Rich Year
  • 07/05/2021

This Biotech Stock Is Beating GameStop

  • Now the question is whether the gains are here to stay.
  • 07/01/2021

Is It Too Late to Buy Cassava Sciences Stock?

  • Just because the stock has had a massive run doesn't mean its biggest gains are behind it.
  • 06/26/2021

Could Cassava Sciences Be a Millionaire-Maker Stock?

  • Can this biotech underdog develop an Alzheimer's drug investors can count on?
  • 06/24/2021

Cassava (SAVA) Stock Up on Alzheimer's Candidate Update

  • Cassava Sciences' (SAVA) completes enrollment in its open-label study on simufilam. It plans to begin two pivotal phase III studies on simufilam in the second half of 2021.
  • 06/22/2021

Cassava Sciences (SAVA) is Overbought: Is A Drop Coming?

  • Cassava Sciences (SAVA) has moved higher as of late, but there could definitely be trouble on the horizon for this company
  • 06/22/2021

Why Cassava Sciences Stock Soared Today

  • Investors applauded the company's update on its clinical programs.
  • 06/21/2021

Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer's Disease

  • Selection of Premier Research as CRO Marks Significant Milestone Toward Initiation of Phase 3 Program of Simufilam in Alzheimer's Disease Selection of Premier Research as CRO Marks Significant Milestone Toward Initiation of Phase 3 Program of Simufilam in Alzheimer's Disease
  • 06/21/2021

Why Cassava Sciences Shares Are Moving Today

  • Cassava Sciences Inc (NASDAQ:SAVA) shares are trading higher by 11.2% at $88.50 after the company highlighted clinical development progress and provided guidance on upcoming data releases for simufilam, the company's lead drug candidate to treat Alzheimer's disease. Cassava Sciences is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease.
  • 06/21/2021

Cassava Sciences Stock Gains After Outlining Clinical Development Progress For Lead Alzheimer's Candidate

  • Cassava Sciences Inc (NASDAQ: SAVA) has announced a mid-year update highlighting clinical development progress and providing guidance on upcoming data releases for simufilam and SavaDx.  Simufilam is Cassava's lead drug candidate to treat Alzheimer's disease; SavaDx is an investigational diagnostic candidate to detect Alzheimer's with a simple blood test.
  • 06/21/2021

Cassava Sciences to Present at the Raymond James 2021 Human Health Innovation Conference

  • AUSTIN, Texas, June 17, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that it has been invited to present at the Raymond James 2021 Human Health Innovation Conference, a virtual event taking place on June 21-23, 2021.
  • 06/17/2021

These 2 Biotech Stocks Are Up 1,000% This Year

  • New approaches to treating Alzheimer's could mean even bigger gains in the future.
  • 06/16/2021

Cassava Sciences Announces the Appointment of Richard J. Barry to its Board of Directors

  • - Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and Societal Goals –
  • 06/14/2021

Why Cassava Sciences Was Up 15% in May

  • Thanks to key funding, its Alzheimer's drug is on track even after Biogen's historic approval.
  • 06/07/2021

Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment

  • Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.
  • 06/02/2021

Are Options Traders Betting on a Big Move in Cassava Sciences (SAVA) Stock?

  • Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
  • 05/25/2021

Annovis' Alzheimer's Drug Is Interesting, Cassava's Looks Better

  • Annovis Bio tripled Friday after reporting exciting Alzheimer's data. Its drug posiphen is not clearing plaques or flooding receptors, but inhibits amyloid-β precursor protein from translating toxic Aβ.
  • 05/24/2021

Cassava Sciences to Participate in Q&A Panel Discussion on Alzheimer's Disease

  • - Virtual Panel to be Held on Wednesday, May 26 th , 11:00am Eastern Time -
  • 05/24/2021

Long-Term Small Molecule Studies Bode Well For Cassava Sciences' Alzheimer's Data

  • The only effective Alzheimer's treatment on the market is aricept, but its effect falls off after six months because it simply floods receptors.
  • 05/18/2021

Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development

  • Caladrius Biosciences Inc (NASDAQ: CLBS) has received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority. The Program enables qualifying companies to sell a percentage of their New Jersey net operating losses and research and development tax credits to unrelated qualifying corporations.
  • 05/12/2021

Cassava Sciences Announces New $2.7 Million Research Grant Award from National Institutes of Health

  • - Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam - - Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam -
  • 05/12/2021

Buying Cassava Sciences Ahead Of July Data

  • The stock is off >70% from February high after going up 3x after the interim Alzheimer's data. Targeting $70 by the second interim data release in July (70% upside potential).
  • 05/10/2021

Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer's disease

  • - Randomized, Controlled Study is Designed to Evaluate Cognition  in Patients Who Continue Versus Discontinue Simufilam Over Six Months –
  • 05/10/2021

Cassava Sciences Invited to Participate in B. Riley Securities' Neuroscience Conference

  • Fireside Chat on Wednesday, April 28th at 2:30PM Eastern Fireside Chat on Wednesday, April 28th at 2:30PM Eastern
  • 04/27/2021
Unlock
SAVA Ratings Summary
SAVA Quant Ranking